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 1 
Abstract 
 
  Numerous studies have assessed single nutrient and multiple nutrient 
supplements in the treatment of psychiatric symptoms. Recently there has been growing 
evidence suggesting that treatment with broad-spectrum micronutrient supplements 
(Rucklidge et al., 2012), B vitamin combinations (Stough et al., 2011) and vitamin C (Hughes 
et al., 2011) may have benefits for emotional and cognitive functioning. Whether a 
combination of nutrients acting synergistically is more effective than the administration of a B 
vitamin complex or vitamin C alone is yet to be determined. The present study was designed 
to address this question. To investigate this, 40 male and 40 female rats were administered a 
broad-spectrum micronutrient supplement (Berocca), a B vitamin complex supplement, or 
vitamin C alone in their drinking water, for seven weeks. A control group was provided 
unadulterated water.  Animals were then examined through several behavioural measures of 
anxiety and one of short-term memory. The results revealed a number of significant 
behavioural differences between treatment groups, with the Y maze showing the greatest 
number of significant treatment effects. The Berocca group had a significantly higher 
percentage of entries into and occupancy of the changed arm, as well as total entries of both 
arms (ambulation) than all other treatment groups. There were also significant sex x treatment 
interactions in change arm entries and occupancy, with both measures increasing with Berocca 
supplementation in males, and increasing with both Berocca and B vitamin supplementation in 
females. This suggests that different treatments affected each sex differently. Overall rats 
receiving broad-spectrum supplementation (Berocca) showed significantly less emotionality 
and significantly improved short-term spatial memory when compared to other treatment 
groups. 
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1.0 Introduction: 
 
1.1 General Overview 
 
 Anxiety symptoms and disorders represent an ever increasing burden on healthcare 
resources creating a huge strain in terms of social and economic costs (Kessler, 2007; Nutt et 
al., 2007). Currently, anxiety disorders are the most prevalent psychiatric illnesses in Europe 
and the USA (Alonso & Lepine, 2007; Kessler et at., 2005; Kessler, 2007; Nutt et al., 2007). 
Epidemiological studies (Alonso et al., 2004; Kessler & Merikangas, 2004) show anxiety 
disorders have the highest lifetime prevalence estimates of 13.6-28.8% and the earliest age of 
onset (11 years) of psychiatric disorders (Kessler et al., 2005; Kessler et al., 2005; Nutt et al., 
2007). 
 Anxiety has been defined as a future oriented negative mood state associated with 
preparation for possible upcoming negative events, characterised by bodily symptoms of 
physical tension and apprehension about the future (Barlow, 2002). Symptoms of anxiety can 
be mild and transient and may not cause functional impairment in social and occupational 
areas. However for many people symptoms can create a severe and chronic impact on 
functioning across many areas (Baldwin et al., 2005; Cryan & Sweeney, 2011) significantly 
affecting an individuals ability to carry out normal life activities (Pilkington et al., 2006).  
 
1.1.1 Causes of anxiety  
 The pathophysiology behind anxiety disorders is complex and still relatively unknown. 
There is no simple one dimensional cause. Instead it is thought to be associated with biological 
(inherited anxious traits), psychological (belief the world or situations are dangerous) and 
social contributors (Barlow & Durand, 2012) integrating to create a triple vulnerability 
(Barlow, 2002; Barlow & Durand, 2012). Under pressure a given stressor could activate 
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biological and psychological tendencies to feel out of control. Once this cycle begins it feeds 
on itself (Barlow & Durand, 2012). 
 From a neurobiological perspective, anxiety disorders are characterised by a variety of 
neuroendocrine, neurochemical and neuroanatomical disruptions and may also be influenced 
by oxidative stress (Bouayed et al., 2009). Neuroanatomically, a prefrontal-amygdala circuit 
appears to mediate the basic mechanisms involved in human anxiety such as selective 
attention to threats, interpretation of stimuli, the acquisition and extinction of conditioned fear 
(Canteras et al., 2010), the formation and retrieval of emotional and fear based memories 
(Martin et al., 2009). Dysfunction in this circuitry may contribute to the generation of anxiety 
disorders (Canteras et al., 2010; Bishop, 2007). Several pieces of evidence indicate these brain 
regions are similar in rodents and humans (Canteras et al., 2010).  
 These circuits are under the modulation of neurotransmitters and neuroendocrine 
hormones (Martin et al., 2009). The neurochemistry of anxiety has been dominated by focus 
on GABAergic and monoaminergic neurotransmission, based on evidence from effective 
anxiolytics that interact with these systems (Durant, Christmas & Nutt, 2010). The effects of 
anxiolytic drugs that interact with GABAergic systems and GABAergic abnormalities 
associated with anxiety in brain imaging studies (Durant, Christmas & Nutt, 2010), suggests 
increased activity in emotional processing brain regions may be a due to decreased inhibitory 
signalling by gamma-aminobutyric acid (GABA), or increased excitatory neurotransmission 
through glutamate (Martin et al., 2009). Antidepressant drugs that act on monoamine systems 
have implicated a role for serotonin, norepinephrine, and dopamine in the pathogenesis of 
mood and anxiety disorders (Martin et al., 2009).  
 Neuropeptides may also play a role (Martin et al., 2009). One important neuropeptide 
is corticotropin-releasing factor (CRF) which is released via the hypothalamic-pituitary-
adrenal (HPA) axis in response to a threatening stimulus, resulting in the production of 
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glucocorticoids. Prolonged stress can cause dysfunction in the HPA axis and amygdala, 
leading to exposure to high levels of corticosteroids comprimising the hippocampus (HPC). 
This also creates an increase in the activity of ventral prefrontal cortex and amygdala 
(involved in fear based memories) and decreases activity in the dorsal prefrontal cortex and 
nucleus accumbens which mediate an increased sensitivity to aversive events and decreased 
response to rewards respectively (Wilner et al., 2013).  
 Oxidative stress has been implicated in anxiety. Reactive oxygen species (ROS) affect 
a number of physiological functions. When ROS exceed the oxidative capacity of an organism 
(oxidative stress) they induce oxidative damage on cellular components. The brain is highly 
vulnerable to oxidative stress due to its high oxygen consumption, modest antioxidant 
defenses, and lipid-rich constitution (Ng et al., 2008; Halliwell, 2006). In the presence of high 
oxidative stress the lipid rich constitution of the brain favours lipid peroxidation, which results 
in a decrease in membrane fluidity and damage to membrane proteins, inactivating receptors, 
enzymes and ion channels. As a result oxidative stress can alter neurotransmission, neuronal 
function and overall brain activity (Delattre et al., 2005; Lebel, 1991; Cardozo et al., 1999). 
Recently a link between oxidative stress and certain anxiety disorders has been established in 
humans (Kuloglu et al., 2002, 2002a). There has also been links between oxidative and anxiety 
related phenotypes (Hovatta et al., 2005) and anxiety-related behavior (Bouyed et al., 2007). 
  
1.1.2 The effects of anxiety on cognition 
 Patients suffering from anxiety disorders frequently present with other cormorbid 
illnesses including psychiatric disorders such as depression (Kessler et al., 2005) and medical 
conditions (Harter et al., 2003). Of importance to the present study is the association between 
stress and anxiety and cognitive functioning, particularly memory. Human and animal studies 
have indicated anxiety and stress are associated with poorer cognitive functioning (Pittenger, 
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2013). Chronic and uncontrollable stress has numerous effects on plasticity-associated 
processes throughout the brain in rodent models (Pittenger & Duman, 2008, Lupien et al., 
2009; Radley & Morrison, 2005). These include dendritic atrophy, and inhibition of long-term 
potentiation (LTP) in the HPC and frontal cortex (Sapolsky, 2000; Kim & Diamond, 2002; 
Duman, 2004; Dranovsky & Hen, 2006; Lui & Aghajanian, 2008; Radley et al., 2006; 
Goldwater et al., 2009; Pittenger, 2013). 
 Several studies have found structural brain abnormalities in people with anxiety 
disorders (Mataix-Cols & van den Heuvel., 2006; Phan et al., 2009; Szezko et al., 2005; van 
den Heuvel et al., 2005), that could be linked to neuropsychological deficits (Casteneda et al., 
2011). Research suggests brain structures subserving episodic memory functioning are 
affected in anxiety disorders (Araksinen et al., 2005). In a population-based study, 
impairments in verbal episodic memory and executive functioning in anxiety disorders in 
general were found, with the nature of the dysfunction depending on subtype (Araksinen et al., 
2005).  
 In terms of specific anxiety disorders, research based on cognitive function of OCD 
has demonstrated episodic memory impairments for both verbal (Dison, 1995; Savage et al., 
1996, 1999) and non-verbal information (Savage et al., 2000; Zitterl et al., 2001) and 
performance deficits in executive functioning (Mertinot et al., 1990; Parcell et al., 1998a,b; 
Veale et al., 1996; Head et al., 1989) and visual memory (Casteneda et al., 2011). Deficits 
have also been found in PTSD in verbal and visual memory and attention (Brewin et al., 2007; 
Golier & Yehud, 2002; Johnsen & Asbjornsen, 2008; Horner & Hamner, 2002). More 
information is needed for other anxiety disorders (Casteneda et al., 2011).  
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1.1.3 Current Pharmacological treatments for Anxiety  
 Over the last half century pharmacological treatments for anxiety disorders have 
become more tolerable, available and numerous (Farach et al., 2012). However despite these 
advances, between one third and one half of patients treated with current medications do not 
achieve sustained remission from anxiety (Pollack et al., 2008). To date, the main 
psychopharmacological treatments for anxiety are benzodiazepines and antidepressant (SSRIs, 
SNRIs, TCAs) medications. 
 Selective-serotonin reuptake inhibtiors (SSRIs) and to a growing degree Serotonin and 
norepinephrine reuptake inhibitors (SNRIs), are considered the first line pharmacological 
treatment for anxiety disorders (Ravindran & Stein, 2010) except for specific phobia. They are 
thought to work by blocking the reuptake of serotonin and norepinephrine, respectively, 
thereby increasing levels of these neurotransmitters at the synapse (Farach et al., 2012). This is 
then thought to start a cascade of downstream effects on other neurotransmitters, intracellular 
second messangers, and immediate early genes (rapidly activated) producing long term 
chemical changes in the brain (Kirshman & Nestler, 2008). This includes influences on 
intracellular neurotrophic factors, neurogenesis in the hippocampus, and the HPA stress 
response system (Wilner et al., 2013).  
 SSRIs have been touted as efficacious for a range of psychiatric disorders. They have 
been reported to have relatively fewer side effects and a low potential for abuse compared to 
other pharamcological treatments. They are also safer and more tolerable than older TCA 
antidepressants (Ravindran & Stein, 2010). However, there are a number of drawbacks to 
SSRIs. To start with, the efficacy has been questioned as they have consistently shown only 
moderate response rates with around 30-40% of patients not responding to treatment (Wilner 
et al., 2013).  Remission rates when treatment has been stopped are also high at around 40% 
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(Tollefson & Hoffman, 1994; Thase et al., 2001). There are serious questions about how 
much, and in whom, the placebo effect contributes to antidepressant response. 
 SSRIs and SNRIS usually take 2-6 weeks to produce a partial response with full 
benefits often not seen for another 4-6 weeks (Montgomery et al., 2002) and in some cases 10-
12 weeks or longer (Tedeschini et al., 2011). They also come with a number of side effects. 
Approximately 30-50% of patients experience mild and transient side effects including nausea, 
diarrhea, headache, insomnia, jitteriness or restlessness, potentially increasing anxiety (Farach 
et al., 2012). Sexual side effects such as diminished interest, performance, and satisfaction 
occur in 30-50% of patients (Farach et al., 2012). Finally, they metabolically interact with and 
change blood levels of other drugs and are associated with a withdrawal syndrome that can 
mimic anxiety when stopped (Farach et al., 2012). Additionally, they have been associated 
with increased suicidal ideation, promoting the USA FDA’s ‘black box’ warning. The lack of 
efficacy and serious side effects can make compliance with treatment difficult (Farach et al., 
2012). 
 Benzodiazepines were initially considered first-line treatments for anxiety because of 
their tolerability and equal efficacy to tricyclic antidepressants (TCAs), but became second-
line options when it became clear that SSRIs were both more tolerable and efficacious. 
Currently, benzodiazepines are primarily used for individuals who have had suboptimal 
responses to antidepressants (Farach et al., 2012). Benzodiazepines bind to a specific receptor 
site on the GABA–A complex and facilitate GABA inhibitory effects by acting on a chloride 
ion channel (Davidson, 1989).  They are used for their potent, short-term effects and to help 
reduce anxiety during the initial weeks of an antidepressant when anxiolytic effects have yet to 
occur (Goddard et al., 2001). The potency of these medications are appealing to the patient but 
not always desirable, as they can reinforce pill taking, serve as a safety signal that undermines 
self-efficacy, and become incorporated into the conditioned fear response (Westra, et al., 
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2002). This is exacerbated when benzodiazepines are taken on an as-needed basis. As-needed 
use links pill taking to rapid reduction in anxiety, powerfully reinforcing avoidance for 
anxiety-provoking situations and encouraging long-term reliance on the drug. This may be one 
reason why benzodiazepines have been associated with reduced response to cognitive 
behavioral therapy (Watanabe et al., 2007). Chronic benzodiazepine use is associated with 
physiological dependence, cognitive (Barker, 2004) and psychomotor impairment, and health 
problems (Pelissolo et al., 2007). Withdrawal from benzodiazepines can result in adverse 
reactions including rebound anxiety, paranoia, insomnia and depression. The effects of 
benzodiazepine withdrawal can ultimately worsen anxiety and potentially cause depression 
(Farach et al., 2012). Despite the advantages of benzodiazepines over previous drugs, their 
long-term use is hampered by dependence liability, tolerance, and cognitive and other 
behavioural side effects (Cryan & Sweeny, 2011).  
 The large number of unpleasant side effects and discontinuation effects associated with 
current pharmacological treatment and more specifically the addictive nature of 
benzodiazepines and inefficacy of antidepressant treatments has led to a search for 
alternatives. The hope being to reduce psychiatric symptoms with fewer side effects and risks 
associated with long-term use, as well as a treatment that is able to produce a response rate as 
good as or better than the current treatments. One area that has been gaining traction/seen an 
increase in investigation recently is the use of micronutrient (vitamins and minerals) 
supplementation in mental health. 
 Vitamin-based products are the most widely used food supplements throughout the 
developed world (Kennedy & Haskell, 2011). There is a wealth of evidence from 
epidemiological studies that clearly suggests a relationship between micronutrients and 
psychological functioning (Kennedy et al., 2010). This is not surprising as the central nervous 
system (CNS) is dependent on a wide range of micronutrients for optimal functioning 
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(Kennedy et al., 2010; Rucklidge & Kaplan, 2013). A number of studies have assessed single 
and multiple micronutrient supplements in the treatment of psychiatric symptoms with recent 
evidence suggesting that treatment with broad-spectrum micronutrient supplements 
(Rucklidge et al., 2012), B vitamin combinations (Stough et al., 2011) and vitamin C (Hughes 
et al., 2011) may have benefits for emotional and cognitive functioning. These effects are 
likely due to correction of micronutrient deficiencies, which may lead to the expression 
psychiatric symptoms, by broad-spectrum micronutrients and B-vitamins (Rucklidge & 
Kaplan, 2013), and the potent antioxidant properties of vitamin C (Cantuti-Castelvetri et al., 
2000; Harrison et al., 2009a,b). Whether a combination of nutrients acting synergistically is 
more effective than the administration of a B vitamin complex or vitamin C alone is yet to be 
determined. The present study is designed to address this question by determining whether a 
broad-spectrum micronutrient supplement (Berocca, a combination of B vitamins and vitamin 
C) has greater benefits than a single nutrient supplement (Vitamin C or B vitamin complex) in 
decreasing anxiety-related behaviour and improving short-term memory in healthy rats.  
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1.2 Micronutrient formulas 
 
 The mixed results that have been reported in relation to single vitamins and minerals 
(Kaplan et al., 2007) and their effects on mental health have lead researchers to start 
investigating the effects of broad spectrum micronutrient formulas (multi-ingredient) may 
have on mental health. This recent shift in research focus has been controversial given the 
scientific method requires that only one independent variable, such as a single micronutrient, 
should be manipulated during an investigation of its effects on dependent variables to reduce 
the number of confounding factors (Kaplan & Leung, 2011). Research involving a number of 
independent variables is thrown out as having too many confounds and therefore interfering 
with the interpretation of results. Following this, designing studies with a multi-ingredient 
formula, as an intervention has required a shift in thinking in scientific and academic fields 
(Kaplan & Leung, 2011).  
 The growing body of research in this area has investigated the effects of micronutrient 
formulas in relation to a number of mental health areas including mood and anxiety disorders 
(Kaplan et al., 2002; Kaplan et al., 2004), ADHD (Rucklidge et al., 2011b) and OCD 
(Rucklidge, 2009). Of relevance to the present study is research showing that supplementation 
with Vitamin C alone (Hughes et al., 2011; Brody et al., 2002; Mazloom et al., 2013; Harrison 
et al., 2009a,b), B-vitamins alone and in combination (Stough et al., 2011; Abraham et al., 
2010; Morales et al., 2010; Lewis et al., 2013), and a broad-spectrum micronutrient 
supplement (particularly Berocca) (Carroll et al., 2000; Kennedy et al., 2010; Cheng et al., 
2004; Halliwell & Kolb, 2003) may be effective in reducing stress and anxiety, and improving 
memory in animals and humans. 
 The recommended dose of Berocca of one tablet per day has been shown to have 
therapeutic benefits in reducing stress and anxiety in humans (Carroll et al., 2000; Kennedy et 
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al., 2010). However both B vitamins and vitamin C have been shown to produce beneficial 
effects on stress or anxiety symptoms at doses higher than in the Berocca formulation (Stough 
et al., 2011; Hughes et al., 2011). This would suggest that a higher dose of two tablets per day 
of Berocca could produce a greater anxiolytic effect. Comparing single micronutrients to a 
broad-spectrum micronutrient supplement at a high dose is useful in determining appropriate 
supplementation and dosage for stress and anxiety. It may also help to determine further 
avenues of research in this area, such as whether deficiencies in a number of micronutrients or 
a single micronutrient contribute to anxiety related behaviour.	 A control group was also 
included in the present study to provide a comparison group of animals not receiving a 
supplementation as well as comparisons between treatment groups.  
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1.3 Assessing anxiety-like behaviour in rats 
 Anxiety is highly conserved during evolution as a vital emotion. Its interaction with 
cognitive parameters regulates behaviour in humans and animals (Ohl, 2005). It allows an 
individual to avoid a perceived threat or dangerous situation. The assessment of anxiety-
related behaviour in rodent models is based on the assumption that anxiety in rodents is 
comparable to anxiety in humans (Ohl, 2005). However it cannot be proved that rodents 
experience anxiety in the same way as human beings (Ohl, 2005). Here the definition between 
anxiety and fear becomes very important. In humans anxiety is defined as a future oriented 
mood state associated with preparation for possible upcoming negative events (Barlow, 2002); 
and fear as an alarm response to present or imminent danger (real or perceived) (Craske et al., 
2009). This is comparable to the animal predatory imminence continuum (Fanselow & Lester, 
1988), whereby anxiety corresponds to an animal’s state during a potential predatory attack 
and fear corresponds to an animal’s state during predator contact (Craske et al., 2009). Models 
where a rodent is placed into a situation they perceive as potentially threatening have allowed 
the determination of distinct behavioural and physiological patterns that undisputedly indicate 
anxiety (Ohl, 2005). From these an association between anxiety in humans and rodents may be 
assumed (Ohl, 2005). 
 
1.3.1 Validity in Animal Models of Anxiety 
 McKinney and Bunney (1969) proposed that an ideal animal model for any human 
clinical condition must fulfill three criteria.  First, to satisfy predictive validity 
pharmacological treatments known to be effective in humans should induce comparable 
effects in the animal model. Therefore for anxiety the model should respond to anxiolytics 
such as benzodiazepines with reduced anxiety (Ohl, 2005). Second, to satisfy face validity, the 
responses or symptoms observed in humans should be the same in the animal model. For 
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anxiety the animal must display defensive or avoidant behaviour when exposed to a 
threatening stimulus (Ohl, 2005). Third, to satisfy construct validity, the underlying rationale 
should be the same in both humans and animal models.  The underlying mechanisms of 
anxiety and its psychological causes must be identical (Ohl, 2005).  
 Due to the heterogeneous forms of pathological anxiety and subjective reports of 
symptoms in humans, meeting all three validity criteria is difficult for an animal model of 
anxiety. However aspects, such as the physiological and behavioural responses to aversive 
stimuli, are similar in humans and animals. This means animal models are useful as 
behavioural tests to screen for potential anxiolytic properties of new drugs and as tools to 
investigate specific pathogenic aspects of primary symptoms of anxiety disorders (Ohl, 2005).  
 
1.3.2 Behavioural expressions and the approach avoidance conflict: 
 The main current behavioural tests of unconditioned anxiety in rodents focus on 
creating an approach-avoidance conflict in the animal (Encanner, 2014). They play on the 
conflicting drives of the animal to explore a novel environment and avoid any potential treat. 
This conflict moderates species-specific behavioral expressions of anxiety. It is well known 
that rodents tend to avoid the unprotected area of a novel environment upon entering it. 
Rodents typically explore the areas of new environments adjacent to the walls while avoiding 
an open area (Prut & Belzung, 2003). The aversive nature of an open area can be modified 
using differing light levels. A brightly lit area is thought to be more aversive for a rodent than 
a dim area and therefore produces more noticeable avoidance behaviour. The elevation of an 
open area is also thought to increase aversive behaviour (Ohl, 2005).  
 Exploratory behaviours encompass a wide range of behavioural patterns such as 
walking, rearing, climbing, sniffing and manipulating objects (Cryan & Sweeney, 2011; Ohl, 
 14 
2005). It is hypothesized that explorative behaviours are inhibited by anxiety and therefore a 
reduction in the above behaviours would indicate an increase in anxiety. Cognitive 
dysfunctions in rats have also been suggested to be interrelated to anxiety-related behavior 
(Ohl, 2003).  
 The current study used four empirically supported behaviour tests. Three were of 
unconditioned anxiety-like behaviour; the emergence latency (light-dark box) in an open field, 
the open field test and an elevated plus maze. The responsiveness to brightness in a Y-maze 
test which is used to examine spatial working memory, has also been shown to be a useful 
index of anxiety (Aitchison & Hughes, 2006). Research to date has shown that known 
anxiolytic agents such as benzodiazepines, busipirone, paroxetine, propanolol and fluoxetine 
have produced a reduction in anxiety-like behaviour in rats using the above animal models 
(Cryan & Sweeney, 2011).  
 The emergence latency (light-dark box), open field and elevated plus maze tests play 
on the conflicting drives of avoidance an exploration of a perceived threatening stimulus (i.e. 
an open space or lit area) (Crawley, 1985; Hascoët & Bourin, 2003; Montgomery, 1955; 
Salum et al., 2003). When a rat is confronted with a novel environment its behaviour is 
determined by the conflict between its drive to explore the unknown area and its motivation to 
avoid potential danger (Ohl, 2003), which is assumed to represent anxiety (Ennaceur, 2014). 
The open field and elevated plus maze also assess exploratory behaviour (rearing, walking and 
grooming) as further indicators of anxiety (Carli et al., 1989; Lamprea et al., 2008; 
Escorihuela et al., 1999; Lepicard et al., 2001; Rodgers & Dalvi, 1997; Espejo, 1997; 
Hannigan & Isaacson, 1981; Kalueff & Tuohimaa, 2004; Kametani, 1988; Torres, 1961; Nin 
et al., 2012).  
 The Y-maze is a well known test of spatial working memory in rats (Kumar et al., 
2013), that is based on the tendency of rodents to explore novel environments (Dellu et al., 
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2000; Ma et al., 2007). Responsiveness to brightness change in a Y-maze has been shown to 
be a useful index of curiosity motivated spatial working/short term memory (Hughes & 
Maginnity, 2007; Hughes & Neeson, 2003; Hughes, 2004). The Y-maze can also be used to 
assess anxiety-like behaviour. Activity in the Y-maze is inversely related to anxiety (Archer, 
1973). It is thought that higher levels of anxiety result in fewer changed arm entries and 
occupation (Aitchison & Hughes, 2006; Aitken, 1974; Hughes, 1987; Misslin & Ropartz, 
1981). 
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1.4 Animal studies with micronutrients 
 To date minimal research has focused on the effects of broad spectrum micronutrient 
supplementation on anxiety-like behaviour in rats. This makes it difficult to predict the types 
of behavioural changes that could be exhibited following supplementation. There is slightly 
more research assessing the effects of individual nutrients on anxiety-like behaviour in rats 
which may provide a guideline for the types and size of behavioural effects expected. More 
specifically, vitamin C has been well researched with a number of studies reporting anxiolytic 
properties. Although there is little research into B vitamin complexes, individual B vitamins 
have shown similar anxiolytic effects. 
 
1.4.1. Broad-spectrum micronutrient supplementation: 
 The majority of research into broad-spectrum micronutrient supplementation has 
focused on human trials. However some animal research has been conducted. The results from 
these studies suggest broad-spectrum micronutrient supplementation may be effective in 
reducing anxiety (Naismith Thomass, 2013) as well as mitigating the effects of stress-induced 
injury and traumatic brain injury on anxiety, memory and neuroanatomical outcomes (Cheng 
et al., 2004; Halliwell & Kolb, 2003; Halliwell, 2003; Hasan et al., 2013). 
 Naismith-Thomass (2013) investigated the effects of the broad-spectrum micronutrient 
formula EMPowerplus (EMP+) on anxiety-like behaviour in rats and the dose related 
anxiolytic effects. Rats received a diet of 0%, 1.25%, 2.5%, or 5% EMP+ for 141 days. 
Animals were tested on behavioural measures of anxiety-like behaviour and memory at mid 
(PND 136-138) and late adulthood (PND 186-188). The highest dose (5%) diet group 
occupied centre squares most and corners the least in an OFT compared to all other groups, 
suggesting a higher dose of EMP+ is associated with the greatest reduction in anxiety related 
behaviour. However this study found no significant differences between any treatment and 
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control groups in another test of anxiety (light-dark box) and a measure of short-term spatial 
memory (responosiveness to brightness in a Y-maze). Furthermore animals were found to 
display more anxiety-like behaviour at late adulthood regardless of receiving a supplemented 
diet or not. It is important to note that this study was interrupted by the September 4th, 2010 
Canterbury earthquake, which may have compromised the results. 
 Cheng et al., (2004) investigated the protective effects of a broad-spectrum 
micronutrient supplement on stress-induced injury established by electric foot shock in rats. 
Rats were fed small, medium and large doses of the micronutrient supplement for 6 weeks. 
Compared to control, rats that consumed the micronutrient supplement exhibited less anxiety-
like behaviour in an OFT, and had lower levels of serum cortisol, epinephrine and 
norepinephrine. A broad-spectrum micronutrient supplement was beneficial in improving 
stress-adapting ability and attenuating stress induced injuries in rats. A further study found 
supplementation with a broad spectrum of micronutrients reduced oxidative changes and DNA 
damage associated with chronic stress in mice (Hasan et al., 2013). 
 Halliwell and Kolb (2003) and Halliwell (2003) examined the effects of EMP+ on 
recovery from early brain injury. Rats lesioned at PND3 in the frontal cortex show drastic 
permanent reductions in cortical thickness and functional performance, including decrements 
on tasks involving motor skill and spatial learning and memory. When tested as adults those 
administered EMP+ in their food throughout their lives showed an increase in brain weight, 
cortical thickness and restoration of functioning in behavioural tasks as well as enhanced new 
dendritic growth and increased spine density. Rats with perinatal post parietal lesions, when 
fed EMP+ showed similar anatomical recovery and restoration of cognitive and motor 
capacity assessed by OFT, water maze, and tray reaching tests. 
 Halliwell et al., (n.d) investigated the effects of chronic stress during pregnancy and/or 
a prefrontal injury in rats on behavioural and anatomical outcomes, as well as the effects of 
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micronutrient supplementation following chronic stress and/or PF injury. It was found that the 
micronutrient treatment improved performance on a number of behavioural measures 
including skilled reaching, latencies in a MWM and exploratory behaviour in the EPM. These 
studies indicate there are some benefits of broad-spectrum micronutrient supplementation for 
cognition and emotionality in both normal and lesioned animals. 
 
1.4.2 B Vitamins: 
 Although little if any research has investigated the effects of a B vitamin complex in 
animals, a number of studies have focused on individual B vitamins. This research has shown 
benefits of acute and chronic supplementation with high doses of specific individual B 
vitamins in anxiety (B6) (Abraham et al., 2010) and memory (B3 and B9) (Morales et al., 
2010; Carletti et al., 2012; Matte et al., 2007) suggesting probable neuroprotective effects as 
well as influences on neurotransmitter systems as the mechanisms behind these effects. 
 Anxiety as well as alterations in serotonergic function in the hippocampus (HPC) are 
thought to be associated with diabetes mellitus. Abraham et al., (2010) found anxiolytic effects 
of 15 days of supplementation with a high dose of pyridoxine (B6) (100mg/Kg of bodyweight) 
in combination with insulin and aegle marmelose (plant extract) in an elevated plus maze 
(EPM) in diabetic rats compared to control non diabetic rats. They also found a normalisation 
of serotonin concentration and gene expression in the HPC to near control. This suggests 
pyridoxine in combination with insulin and aegle marmelose has a role in normalising 
diabetes-related stress and anxiety through HPC serotonergic function.  
 Morales et al., (2010) investigated the neuroprotective effect of acute doses 
(100mg/Kg of bodyweight) of  nicotinamide (B3), administered 24, 48 and 72 hours after 
birth, against perinatal asphyxia in the HPC on behaviour at 30 and 90 days of age in rats. 
Nicotinamide prevented apopotosis in the HPC, working memory deficits in a novel object 
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recognition test and anxiety in an elevated plus maze in perinatal asphyxia compared to saline 
control. The authors proposed nicotinamide may protect against oxidative stress, ischemic 
injury and inflamation. These mechanisms may help prevent anxiety-related behaviour and 
memory impairment following perinatal asphyxia in rats. 
 A Further study (Carletti et al., 2012) investigated the effects of injecting folic acid 
(B9) once a day for 23 days, at a dose of .011 µmol/g of bodyweight, on Wistar rats that 
underwent hypoxia-ischemia (HI) at PND7. Folic acid prevented anxiogenic effects in an OFT 
and impairment of aversive memory in an inhibitory avoidance test of HI rats. This suggests 
potential neuroprotective and anxiolytic effects of folic acid following ischemic injury. 
 Another recent study looked at the effects of folate after induced chronic 
hyperhomocysteinemia (elevated homocysteine) in rats (Matte et al., 2007). Increase in 
homocysteine (Hyc) from a B vitamin deficient diet is hypothesised to contribute to cognitive 
decline. Hyperhomocysteinemia impaired reference memory for platform location in a water 
maze compared to controls. Treatment with folate at a dose of .011 µmol/g of bodyweight, for 
22 days, prevented these impairments. It was suggested these effects were possibly due to its 
antioxidant effects of folate.  
 These studies suggest some anxiolytic and neuroprotective benefits for certain B 
vitamins in animal models. Possible mechanisms include effects on neurotransmitter function, 
oxidative stress, and inflammation. However research in this area is limited, and to date no 
research has looked at a B vitamin complex in animals. 
 
1.4.3 Vitamin C 
 The anxiolytic and cognitive benefits of vitamin C have been well studied in animals. 
It has been implicated in anxiety and psychosocial stress-related behaviour (Hughes et al., 
2011). These effects have been exhibited in poultry (Jones et al., 1996; Satterlee et al., 1994), 
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rats (Hughes et al., 2011), and humans (Brody et al., 2002; Mazloom et al., 2013). A number 
of studies have shown pre-treatment with vitamin C affects indices of fear in poultry, such as 
attenuated tonic immobility and decreased neophobia in Japanese quail (Jones et al., 1996) and 
broiler chickens (Satterlee et al., 1994). It has also been shown to reduce emergence latency in 
a light-dark test in Japanese quail (Jones et al., 1999).  
 Vitamin C has been reported to reduce time spent by mice in dark versus aversive light 
compartment (De Angelis & Furlan, 1995). DeAngelis and Furlan (1995) tested vitamin C and 
oxiracetam on scopolamine-induced amnesia in habituation tests in aged mice using a light-
dark aversion test. Vitamin C alone (at doses of 62.5, 125, 250 mg/kg) or in combination with 
oxiracetam significantly reduced time spent in the dark and prevented significant alteration in 
learning patterns induced by acute scopolamine, compared to control. This suggests both 
anxiolytic and cognitive benefits.  
 Exposure to vitamin C (75-100 mg/kg) for 80 days has been found to markedly 
reduced anxiety in rats (Hughes et al., 2011). This was shown in increases in open field 
ambulation and occupancy of the four centre squares and decreased occupancy of corner 
squares, as well as decreased acoustic startle response. Further studies have shown benefits in 
zebra fish. Puty et al., (2014) treated zebra fish with ascorbic acid (a form or vitamer of 
vitamin C) before methyl mercury (a neurotoxin that causes learning deficits and memory 
impairments and anxiety-like behaviour) exposure. Pre-treatment with vitamin C (2mg/kg) 
blocked significant anxiogenic effects of methyl mercury in a light dark preference model, as 
well as preventing decreases in extracellular serotonin found in controls. 
 One study has investigated the effects of vitamin C supplementation on depression-like 
behaviour and ROS in rats following stress, using a model of chronic unpredictable stress 
(CUS) (Moretti et al., 2012). Just seven days of supplementation with vitamin C (10mg/kg) or 
fluoxetine (SSRI) prevented CUS-caused depressive-like behaviour in a tail suspension and 
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splash test. Vitamin C and fluoxetine also prevented oxidative damage found in controls. 
These studies provide evidence that vitamin C has been shown to reduce anxiety-like 
behaviour in the animal models used in the current study. It has also been as effective as 
current mainstream treatment (SSRIs) in preventing depression-like behaviour. 
 Vitamin C may also slow age-related degeneration of the CNS and associated 
cognitive decline especially in the presence of neurodegenerative diseases (Cantuti-Castelvetri 
et al., 2000; Martin et al., 2002; Morris et al., 1998, 2002). Evidence from animal research 
shows improvements in learning and memory following vitamin C treatment (Arzi et al., 
2004; Harrison et al., 2009a,b; Hasanein & Shahain 2010; Hughes et al., 2011). Using the 
passive avoidance method (learning and memory) to assess cognitive function, Arzi et al. 
(2004), found chronic vitamin C treatment (300mg/kg) significantly improved cognitive 
function compared to control in aged mice. Hasanein and Shahain (2010) also found 
improvements in learning and memory in diabetic mice after chronic vitamin C (50 mg/kg) 
administration. Harrison et al. (2009a), showed acute administration of vitamin C (125 mg/kg) 
in APP/PSENI mice (mouse model of Alzheimer’s disease) improved performance in tests of 
learning and memory.  In another study Harrison et al. (2009b) found acute vitamin C (125 
mg/kg) administration partially attenuated scopolamine-induced cognitive deficits in Morris 
water maze performance in young mice. 
  Parle and Dhingra (2003) used exteroceptive (EPM, passive avoidance tests) and 
interoceptive (scopolamine, diazepam, aging) tests in mice to assess the effects of vitamin C 
(60 and 120 mg/kg) on anxiety-like behaviour and cognition. Vitamin C improved learning 
and memory of aged mice in the passive avoidance test and provided protection for young 
animals from scopolamine and diazepam induced memory impairment. Mhaidat et al (2015) 
found vitamin C (150 and 500 mg/kg) prevented oxidative stress in the HPC and impairments 
in short and long-term memory in a radial arm water maze following chronic sleep 
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deprivation. Finally, An et al (2015) found administration of vitamins C (300mg/kg) and E for 
7 days to Wistar rats that had been administered melamine, significantly ameliorated cognitive 
deficits induced by melamine. This was assessed using a Morris water maze. Both vitamins 
also prevented oxidative damage to the HPC and ameliorated HPC apoptosis. 
 This research suggests benefits of acute and chronic vitamin C supplementation, at 
high and lower doses, on learning and memory in animal models. The anxiolytic and cognitive 
benefits found in these studies are likely due to vitamin Cs powerful antioxidant action. 
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1.5 Human studies with micronutrients 
 
1.5.1 Broad-spectrum micronutrient supplementation: 
 Over the last decade a number of well-conducted trials have investigated the impact of 
broad spectrum micronutrient supplementation on stress, anxiety, and cognition, reporting 
benefits in both healthy and stressed individuals (Rucklidge & Kaplan, 2013). A number of 
studies have focused on the effects of the broad-spectrum micronutrient supplement EMPower 
plus (EMP+). In a randomised controlled trial Rucklidge et al., (2012) showed 
supplementation with Berocca (one tablet per day) and varying doses (low, medium and high) 
of CNETM (an identical formula to EMP+) reduced psychological symptoms of stress and 
anxiety in adults experiencing heightened anxiety/stress 2-3 months after an earthquake 
compared to control. In an open label trial, Rucklidge et al., (2011) reported that 8 weeks of 
treatment with EMP+ produced significant improvements in mood, anxiety and stress in adults 
with both ADHD and severe mood dysregulation. Positive effects of EMP+ treatments have 
also been reported in OCD with children (Kaplan et al., 2002; Kaplan et al., 2004; Rucklidge, 
2009, Frazier, et al., 2009, 2012; Rodway et al., 2012) and adults (Rucklidge, Taylor & 
Whitehead, 2011; Kaplan et al., 2001). 
 Three double blind, placebo controlled trials have looked at the effects of Berocca 
supplementation on stress and anxiety. Carrol et al., (2000) showed 28 days of Berocca 
supplementation (one tablet per day) significantly reduced anxiety and perceived stress 
compared to placebo in healthy men. Investigating psychometric measures of stress in patients 
with high stress levels, Schlebusch et al., (2000) found a significant degree of improvement 
with Berocca (one tablet per day) treatment compared to placebo. Kennedy et al., (2010) 
found Berocca (one tablet per day) supplementation lead to improved ratings of stress, mental 
health and vigour, as well as improved cognitive performance during intense mental 
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processing compared to placebo. These results suggest broad-spectrum micronutrient 
supplementation may be effective in reducing anxiety and stress, and show some potential for 
improving cognitive performance in healthy and stressed individuals.  
 The extent to which broad-spectrum micronutrient supplementation improves 
cognition is uncertain (Pipingas et al., 2014), with several studies demonstrating no impact on 
cognitive performance (Cockle et al., 2000; Wolters et al., 2005), while more recent studies 
suggest potential benefits (Harris et al., 2012; Macpherson et al., 2012; Haskell et al, 2010). A 
recent meta-analysis (Grima et al, 2012) of ten trials showed one month of multivitamin 
supplementation produces some improvements in immediate recall, but no other cognitive 
domains. Another meta-analysis (Eilander et al., 2010) of 12 randomised controlled trials in 
healthy children (ages 5–16) found no significant effects on cognitive processing speed, 
working memory and long-term memory. However, four trials included in the analysis showed 
benefits in academic performance in school-age children (Magner et al., 2008; Schoenthaler et 
al., 1991; Vazir et al., 2006; Wang et al 2003). 
 A number of recent randomised placebo controlled trials have provided evidence that 
broad-spectrum micronutrient supplementation may yield some benefits in cognitive 
performance in adults and elderly populations. In a placebo controlled, double blind 
investigation, Harris et al., (2012) found 8 weeks of a multivitamin, mineral and herbal 
supplement (one tablet per day of Swisse Men’s Ultivite) significantly improved episodic 
memory in middle-aged to elderly men compared to placebo. Macpherson et al., (2012) 
conducted a further randomised, double blind, placebo controlled trial to investigate the effects 
of a multivitamin, mineral and herbal supplement (one tablet per day of Swisse Women’s 50+ 
Ultivite) on elderly women (aged between 64-82 years). They showed that 16 weeks of 
supplementation improved the speed of spatial working-memory compared to placebo. 
However they found no improvements with supplementation on measures of attention or 
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verbal memory compared to placebo. In a placebo controlled, double blind, randomised trial 
Haskell et al. (2010), investigated the effects of a multivitamin/mineral supplement (Supradyn, 
one tablet per day) on measures of cognitive function and fatigue in healthy females (aged 25-
50 years). They found improvements on a computerised multitasking framework consisting of 
memory search, mathematical, stroop and numerical processing tasks after 9 weeks of 
supplementation compared to placebo. Therefore, although the evidence is inconsistent some 
results suggest broad-spectrum micronutrient supplementation may benefit cognition. 
 
1.5.2 B Vitamin Complex Supplementation: 
 As well as studies that specifically investigated Berocca (mentioned above), two 
studies have shown supplementation with a B vitamin complex reduces stress or anxiety in 
humans. In a randomised double-blind placebo-controlled trial, Stough et al. (2011) 
investigated the efficacy of 3 months administration of a B vitamin complex on mood and 
psychological strain associated with chronic work stress. The B vitamin complex group 
reported significantly lower personal strain and a reduction in confusion and 
depressed/dejected mood as compared with the placebo group, suggesting a decrease in the 
experience of workplace stress. Another randomised double-blind placebo-controlled trial 
(Lewis et al, 2013) evaluated the efficacy of a B vitamin complex for improving depressive 
and anxiety symptoms in adults diagnosed with a depressive disorder. The B vitamin complex 
group showed significant and more continuous improvements in depressive and anxiety 
symptoms, compared to placebo.  
 A number of cross-sectional studies have investigated B vitamin deficiency effects on 
mental health. Sanchez et al (2009) found an association between low blood B vitamin levels 
or high serum homocysteine and higher prevalence of depressive symptoms. This study was a 
cross-sectional analysis of 9670 participants using a validated semi quantitative food 
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questionnaire to ascertain vitamin intake. Similar results have been reported in a number of 
cross-sectional (Hvas et al., 2004; Ramos et al., 2004; Tolmunen et al., 2004; Sacholev et al., 
2005) and case control studies (Lee et al., 1998; Tiemeir et al., 2002). Furthermore, a cross-
sectional analysis of the West Australian Pregnancy Cohort (Raine) study (Herbison et al., 
2012), found lower intakes of vitamins B1, B2, B3, B5, B6 and folate (B9) were associated 
with higher externalizing behavior (aggressive/delinquent) scores and reduced intake of B6 
and folate were associated with higher internalizing (withdrawn/depressed) behaviour scores.  
 B vitamins play key roles at all levels of brain function (Kennedy & Haskell, 2011). It 
is therefore not surprising that a relationship exists between dietary consumption of B vitamins 
and cognitive performance. This has been investigated in cross-sectional and prospective 
studies of the elderly (Stough et al., 2011), revealing positive relationships between cognitive 
performance and B vitamin intake coupled with a negative relationship between cognitive 
performance and levels of plasma homocysteine (high in B vitamin deficiency, Del Parigi et 
al., 2006). B vitamin deficiency may be a casual factor in cognitive decline and dementia as a 
result of subsequent elevation in homocysteine levels (Kennedy & Haskell, 2011). Smith 
(2008) identified a total of 84 cross-sectional studies and 25 prospective studies that addressed 
this issue. Of these, 77 of the cross-sectional studies, involving more than 34 000 subjects, 
showed a negative relationship between cognitive deficits or dementia and the status of folate 
(B9), B6 or B12 and a positive relationship with homocysteine levels. However numerous 
reviews on the effects of B-vitamin supplementation in demented and cognitively intact 
cohorts have concluded that there is a lack of evidence to date for efficacy of these vitamins 
regarding cognitive function (Kennedy & Haskell, 2011). 
 A recent prospective longitudinal cohort study of 7030 postmenopausal women free of 
MCI/probable dementia, found folate intake below RDA at baseline was associated with 
increased risk of incidence of MCI/probable dementia after controlling for multiple 
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confounders (Agnew-Blias et al., 2014). However, there was no significant association with 
other B vitamins. Although the research into B vitamin supplementation is limited, the studies 
presented here provide some evidence that supplementation may benefit anxiety, mood and 
cognition. 
 
1.5.3 Vitamin C Supplementation: 
 Animal research has implicated Vitamin C as an effective in agent in reducing anxiety 
and psychosocial stress-related behaviour (Hughes et al., 2011). These effects have also been 
shown in humans (Brody et al., 2002; Mazloom et al., 2013; Chui & Greenwood, 2008; Zhang 
et al., 2011). In a randomized double-blind placebo controlled trial with healthy young adults, 
Brody et al. (2002) found high dose vitamin C (3000mg/day) reduced blood pressure, 
subjective and state anxiety responses to acute psychological stress, and improved cortisol 
recovery after a stressor. Furthermore a randomized, placebo-controlled, single-blinded trial 
(Mazloom et al 2013) found vitamin C supplementation (1000mg/ day) significantly reduced 
anxiety in diabetic patients measured by a depression anxiety stress scale. These results 
suggest vitamin C may have a positive role in diminishing anxiety in humans. Zhang et al, 
2011 examined in a double blind clinical trial the effects of vitamin C (500mg 2x /day) or 
vitamin D (1000IU 2x /day) on mood (POMs) in non-psychiatric hospitalised patients. 
Vitamin C therapy was associated with a 34% reduction in mood disturbances. These results 
suggest high dose vitamin C supplementation may be useful in reducing anxiety and 
improving mood. 
 In terms of effects on cognition and memory, one study, Chui and Greenwood (2008) 
found that consumption of 1000mg vitamin C and 800IU of vitamin E with a meal prevented 
meal-induced performance deficits on measures of delayed verbal recall (word list, paragraph 
recall) and working memory (digit span) in adults with type 2 diabetes mellitus. Memory 
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impairment is often observed in adults with type 2 diabetes mellitus with further acute deficits 
after meal ingestion.  
 Further research has investigated dietary intake and blood levels of vitamin C, and its 
effects on cognition and Alzheimer’s Disease (AD). A number of large population studies 
have investigated associations between risk for AD and vitamin C intake. One study with data 
from the Chicago Healthy aging project found no dementia free participants aged over 65 
developed AD over a follow up (mean of 4 years) when supplementing with vitamin C 
(Morris et al., 1998). However, other studies have found no beneficial effects of vitamin C 
intake on dementia (Gray et al., 2008; Luchsinger et al., 2003). The Honolulu Asia Aging 
Study (Masaki et al., 2000) found a more complex pattern (Harrison et al., 2014) with men 
aged 71-93 years. Higher vitamin C intake was associated with enhanced cognitive 
functioning in cognitively intact individuals and a lower likelihood of vascular dementia. 
However, there was no relationship between AD and vitamin C intake. The Rotterdam Scan 
Study (Engelhart et al., 2002) reported an 18% reduced relative risk for AD with higher 
vitamin C intake. 
 Higher blood vitamin C levels have been associated with improved cognitive function. 
Goodwin et al., (1983) showed higher plasma vitamin C was associated with improved verbal 
memory recall and mathematical calculations. Furthermore Gale et al. (1996) reported 
significantly increased risk for cognitive impairment in those with depleted plasma vitamin C 
or very low intake. Higher plasma vitamin C has also been associated with better free recall, 
recognition and vocal but not working memory in men over 65 (Perrig, Perrig & Strahelin, 
1997). Although research into vitamin C supplementation in humans is limited, results from 
studies assessing dietary intake and blood levels suggest an association between vitamin C and 
cognitive performance. 
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1.6 Proposed mechanisms of action 
 
1.6.1 Broad-spectrum micronutrient supplementation: 
 The rationale of broad-spectrum nutrient combinations for the treatment of psychiatric 
symptoms is based on human physiology. Many nutrients are required together in balance for 
optimal functioning. Dietary supplements with single nutrients may upset this balance and 
create deficiencies in other nutrients (Rucklidge and Kaplan, 2013). Mertz (1994) suggested 
single nutrients may create imbalances or deficiencies in other nutrients with any substantial 
change of one nutrient for extended periods affecting the requirement for other nutrients with 
which the first interacts. Single nutrient supplementation may be too simple and does not 
account for hundreds of interactions among nutrients (Mertz 1994).  
 Kaplan and Leung (2011) have proposed seven mechanisms by which micronutrients 
could influence mental function. They proposed broad spectrum micronutrient 
supplementation may help to correct in-born errors in metabolism, deficient methylation, 
alterations in gene expression, long latency effects (triage theory), down-regulation of 
micronutrient receptors, impaired growth and development of neurons and impaired 
mitochondrial functioning. These mechanisms are not mutually exclusive but may intertwine 
and overlap, working in conjunction with one another to alleviate mental illness. 
 Mental illness with a well-established genetic predisposition may be the result of 
inborn errors in metabolism that slow metabolic activity involving neurotransmitters in the  
brain. In-born errors in metabolism of key neurobiological pathways (i.e synthesis and uptake 
of neurotransmitters) may affect brain function because micronutrients are involved in many 
enzyme reactions, as cofactors, in the synthesis and metabolism of neurotransmitters. 
Deficiencies in these essential cofactors would lead to depletions in neurotransmitters essential 
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for optimal functioning and could impair ability to utilise nutrients, thereby contributing to 
psychiatric symptoms.  
 Micronutrient treatment may facilitate or correct that metabolic activity. Evidence 
shows at least a third of all known genetic mutations diminish binding affinity for a coenzyme 
by a known enzyme (Ames, 2004). Therefore suboptimal coenzyme (micronutrient) levels 
could decrease binding affinity and lower metabolic activity. Genetic diseases associated with 
this defect are in most cases treatable with micronutrients (Ames, Elson-Schwals & Silver, 
2002). 
 Methylation (the addition of a methyl group [CH3] to a molecule) is an essential 
biological function involved in gene regulation, enzyme activation and the regulation of 
protein synthesis. DNA transcription and neurotransmitter synthesis are dependent on 
methylation processes. Micronutrients play a central role in methylation activity. 
Supplementation may enhance methylation of important brain enzymes, resulting in enhanced 
neurotransmitter synthesis (Kaplan & Leung, 2011). 
 There appears to be a strong genetic component for most mental disorders (Ames, 
2004).  However genetic effects on their own are not deterministic. Nutrition may be able to 
influence gene expression. This is supported by research in the fields of nutrigenomics and 
epigenetics, showing nutrient status is a strong modifier of genetic expression (Kaplan & 
Leung, 2011). 
 The triage hypothesis proposed by Ames (2004) posits that nature ensures our survival 
by rebalancing our metabolism when the availability of micronutrients is inadequate. Any 
available micronutrients are directed towards processes essential for immediate survival at the 
expense of long term health. This may be relevant to many individuals who do not present 
with mental illness until later in life. Mental disorders may reflect cumulative effects of the 
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body triaging suboptimal micronutrient levels that are critical for survival at the expense of the 
brain (Kaplan & Leung, 2011). 
 Impaired brain activity in the mentally ill may in some cases result from inherited 
deficiencies in protein regulation by micronutrient receptors. The basis of this theory comes 
from results of a recent study (Miler & Dulay, 2008) showing postmortem brain tissue from 12 
patients with schizophrenia was significantly deficient in a particular protein critical for a 
niacin receptor. Though these results are specific to niacin, analogous processes related to 
other micronutrients may be unmasked in the future (Kaplan & Leung, 2011). 
 There is a large and growing body of literature showing reductions in brain tissue in 
association with poor mental health (Cotter et al., 2001; Keller et al., 2003; Smiley et al., 
2009; Janssen et al., 2008). Studies on cortical thinning have demonstrated that changes are 
progressive (Keller et al., 2003). It may be that long-term experience of suboptimal nutrition, 
especially in an individual with a genetic predisposition, results in diminished capacity to 
maintain and initiate neuronal growth and development, producing a vulnerability to mental 
illness (Kaplan & Leung, 2011). 
 In a variety of neurological and psychiatric disorders the underlying pathophysiology 
has been demonstrated to induce mitochondrial dysfunction (Kato & Kato, 2000; Young, 
2007; Gardener & Boles, 2005). Elevated levels of oxidative stress have also been implicated 
in neuronal damage in humans and in animal models of brain dysfunction (Wang et al., 2009). 
The primary treatment for mitochondrial disorders is micronutrients and carnitine (an amino 
acid). This suggests psychiatric disorders may be the result of cumulative deficiencies of 
micronutrients needed to deal with oxidative stress (Kaplan & Leung, 2011). Broad-spectrum 
micronutrient supplementation may correct these deficiencies and provide sufficient 
micronutrients to restore metabolic function, alleviating psychiatric symptoms (Rucklidge & 
Kaplan, 2013). 
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1.6.2 B Vitamin Supplementation: 
 The B vitamins play key roles at all levels of brain function (Kennedy & Haskell, 
2011). They function as coenzymes and precursors to cofactors for many enzymatic processes 
involved in cellular metabolism (Kennedy & Haskell, 2011). They have essential involvement 
in every aspect of energy metabolism, including oxidative carboxylation reactions (B1), the 
Krebs cycle (B1, B5), redox reactions (B3), the metabolism of polysaccharides, lipids and 
proteins, and the mitochondrial respiratory chain (B2, B3) (Kennedy & Haskell, 2011). 
 Thiamine (B1) acts as a coenzyme for several metabolic pathways. In its triphosphate 
form, thiamine is somehow involved in nerve membrane function (Ball, 2004). It appears to 
control the functioning of voltage-gated ion channels by stabilizing the density of negative 
charges at the inner side of the nerve membrane (Fox & Duppel, 1975), potentially playing a 
role in the opening of chloride ion channels and influencing postsynaptic neuronal inhibition, 
by functioning as a membrane stabilizer (Bertendorff et al., 1990). Butterworth (1982) 
reported changes in the concentration or metabolism of monoamine neurotransmitters (NA, 
5HT), GABA and acetylcholine in the brains of pyrithamin (an inhibitor of thiamine 
metabolism) treated animals. It is certain that thiamine modulates cognitive performance 
(Elsinger, 1997) especially in the elderly (Kanofsky, 1996). Deficiency in thiamine may also 
contribute to the development of AD (Glaso et al., 2004). Thiamine supplementation may act 
to reduce anxiety through its influences on neuronal inhibition, GABA and monoamine 
neurotransmitters, as well as providing neuroprotection to prevent cognitive impairments. 
 Riboflavin (B2) in its coenzyme forms (FMN and FAD) is important in key metabolic 
reactions involved in the conversion of folate (B9) and pyridoxine (B6) into their coenzyme 
forms. Both FAD and FMN function as coenzymes in a number of oxidoreductive processes 
including involvement in monoamine oxidase (breakdown of monoamines). They are 
necessary for reactions involving other vitamins.  For example, pyridoxine phosphate oxidase 
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is an FMN dependent enzyme that converts pyridoxamine phosphate to pyridoxal phosphate, 
the primary B6 coenzyme. An FAD dependent hydroxylase is involved in the synthesis of 
tryptophan, a precursor to serotonin. FAD dependent enzymes are also involved in folate 
metabolism (Ball, 2004). Riboflavin also ensures the balance of B1 and B3 (Bourre, 2006). Its 
role appears to ensure there vitamins are transformed into appropriate cofactors. 
 Niacin (B3) plays a major role as a coenzyme in the transfer of electrons from 
metabolic intermediates in a number of pathways. Deficiency in niacin results in pellagra, a 
disease with neurological and neuropsychiatric symptoms including irritability, anxiety, and 
depression with dementia sometimes occurring in severe and chronic cases (Ball, 2004). It has 
been proposed to protect against oxidative stress, ischemic injury and inflammation (Zhang et 
al., 1995) and prevents apoptosis in the brain likely by stimulating neurogenesis (Morales et 
al., 2010). Niacin may play a role as an anxiolytic and neuroprotective agent by reducing 
oxidative stress in the brain and enhancing neurogenesis, which have both been linked to 
anxiety and cognitive impairments. 
 Pantothenic acid’s (B5) biological activity is attributable to its incorporation into the 
molecular structures of coenzyme A and its acyl carrier protein. Deficiency in rodents’ can 
result in necrosis and hemorrhage of the adrenal glands. This can impair adrenal endocrine 
functioning and create dysfunction in the HPA axis. In humans, clinical observations include 
irritability restlessness and insomnia as well as adrenocortical insufficiency (Ball, 2004). 
Pantothenic acid may benefit anxiety and stress by normalizing adrenocortical functioning. 
 Pyridoxine (B6) concentration in the brain is 100x greater than in the blood. It ensures 
the synthesis of chemical modulators to combat asthenia, irritability and depression. It acts as 
a coenzyme for amino acid decarboxylases in the synthesis of biogenic amines including 
GABA, dopamine and serotonin. Vitamin B6 is a cofactor for aromatic L-amino acid 
decarboxylase (AADC), an enzyme that catalyzes the conversion of L-DOPA to dopamine, 
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and hydroxytryptamine (5-HTP) to serotonin (Boadle-Biber, 1993). It plays a role in 
tryptophan metabolism and increases the production of serotonin (Galderon-Guzman et al., 
2004). Vitamin B6 has also been shown to regulate the levels of 5-HTP (Calderón-Guzmán et 
al., 2004). There is evidence it plays a role in the modulation of steroid hormones including 
corticosteroids (Ball, 2004). These roles in monoamine neurotransmitter synthesis and in the 
modulation of stress hormones may explain potential anxiolytic effects of B6. 
 Folate (B9) plays a number of roles in the brain. It supplies the methyl group for the 
conversion of methionine to S-adenosylmethionine (SAMe), and therefore plays a role in the 
synthesis and integrity of DNA, and the methylation of proteins, phospholipids, and 
monoamine and catecholamine neurotransmitters (Kennedy & Haskell, 2011). Folate and 
vitamin B12 are required for processes involved in the synthesis and metabolism of 
monoamine neurotransmitters (Bottiglieri, 1996). Together these vitamins may provide 
benefits in anxiety by helping to normalize monoamine neurotransmitter synthesis and 
metabolism. 
 Folate plays an essential role in the synthesis of some of the nucleotides required for 
DNA synthesis. Folate deficiency may reduce methylation of cellular DNA and 
neurotransmitters (Gospe et al., 1995; Mazzerello et al., 1990) therefore impede neural 
function. Folate deficiency has been shown to have significant effects on DNA. Deficiency 
can cause chromosomal brakes, which result in loss of oligodendrocytes and demyelination. 
This in turn contributes to cognitive defects (Blount, 1997). 
 Neurological and neuropsychiatric changes associated with B12 deficiency include 
irritability, memory disturbances, mild depression and apathy. These changes reflect an 
inability to manufacture lipid content of myelin, which results in generalized demyelination of 
nerve tissue. B12 deficiency results in neural tissue deprived of a vital substrate, SAM, which 
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is required for myelination (Ball, 2004). Correcting B12 deficiency may help in the re-
myelination of the CNS and return functioning to normal. 
 One hypothesised mechanism of the potentially beneficial effects of B-vitamins on 
cognitive function is their role in maintaining optimum homocysteine levels. Folate, B12 and 
B6 are implicated in the metabolism of homocysteine, which is produced as a by-product of 
methionine metabolism. Normally, homocysteine is converted back to methionine or used to 
create cysteine and other substances in the body. However, deficiencies in these vitamins may 
block this conversion leading to elevated homocysteine levels (Stough et al., 2011). Adequate 
levels of folate and B12 are also required for the re-methylation of homocysteine, while B6 
plays a key role in this process as a coenzyme in the metabolism of homocysteine to cysteine 
(Mattson & Shea, 2003). Blocking of the conversion process (e.g. by deficiencies of folate 
and/or vitamins B6, B12) leads to elevated levels of homocysteine, which in turn may 
contribute to a range of neurodegenerative and psychiatric disorders (Reynolds, 2006). An 
association between stress and homocysteine levels also exists (Kang et al., 2005; Stoney, 
1999). B-vitamin supplementation may therefore prove effective as a preventative strategy for 
stress reduction and cognitive decline by normalizing homocysteine levels. 
 
1.6.3 Vitamin C Supplementation:  
 Vitamin C is transported into the brain against a steep concentration gradient, and 
accumulates at high concentrations in neuron-rich areas such as the hippocampus, cortex and 
cerebellum (Meffors et al., 1981; Mun et al., 2006). It has both antioxidant and nonantioxidant 
roles in the brain. In its role as a single electron donor, vitamin C is a powerful antioxidant, 
reducing oxygen, sulfur and nitrogen-oxygen radicals generated during normal cellular 
metabolism, and recycling other radicals to their previous forms (e.g. tocopheroxyl to a-
tocopherol). It also contributes to the synthesis of tyrosine, carnitine, catecholamine 
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neurotransmitters and peptide hormones, (Padayatty et al., 2003) and plays roles in neural 
maturation, and as a neuromodulator of the activity of acetylcholine and the catecholamine 
neurotransmitters (Harrison & May, 2009)  
 The anxiolytic and cognitive benefits may be due to vitamin C’s potent antioxidant 
properties (Cantuti-Castelvetri et al., 2000; Harrison et al., 2009a,b; Hughes et al., 2011). 
Vitamin C is a potent scavenger of free radicals. It plays an essential role in the CNS as a 
single electron donor, acting as a powerful antioxidant, reducing oxygen, sulfur and nitrogen-
oxygen radicals generated during normal cell metabolism and recycling other radicals to their 
previous forms (Kennedy & Haskell, 2011). It is an effective scavenger of all aggressive ROS 
within the aqueous environments of the cytosol and extracellular fluids. It reacts with free 
radicals to produce ascorbyl radical and detoxified products through a range of single electron 
transfers (Ball, 2004), as well as supporting and regenerating cellular oxidative defence 
mechanisms (Harrison et al., 2014)  
 Therefore possible neuroprotective effects and cognitive benefits are likely the result 
of reduced oxidative stress-related neural damage (Martin et al., 2002). These antioxidant 
properties might also be responsible for the vitamin's anxiolytic effects (Hughes et al., 2011), 
as oxidative stress has been implicated in anxiety (Bouayed et al., 2009).  
 However, vitamin C’s anxiolytic effects may not be a result of its antioxidant 
properties alone. Its concentration is higher in the brain than almost all other organs. It acts as 
a cofactor for dioxygenase enzymes in the synthesis of DA, NA, and 5HT. It is also vital for 
neuronal repair and new cell generation, and may play a direct role in the transcription and 
expression of hundreds of different genes (Harrison et al., 2014). Furthermore it modulates 
neurotransmitter systems in the brain by regulating receptor synthesis and facilitating the 
release of neurotransmitters (Ball, 2004; Harrison & May, 2009), including the inhibition of 
NMDA receptor activity (Majewska et al., 1990). This could lead to decreased anxiety since 
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NMDA antagonism has been shown to be anxiolytic in rats and mice in a similar fashion to 
benzodiazepines (Plaznik et al., 1994). 
  Vitamin C is involved in neural maturation enhancing differentiation of embryonic 
stem cells into neurons in culture (Lee et al., 2000). It is associated with increased expression 
of genes involved in neurogenesis, maturation and neurotransmission (Shin et al., 2003). It has 
been proposed to function as a neuromodulator of DA and glutamate-mediated 
neurotransmission (Rebec & Pierce, 1994; Grunewald, 1993), and in the regulation of both 
acetylcholine and catecholamine release from synaptic vesicles (Kuo et al., 1979). 
Furthermore it has been shown to attenuate levels of the stress-related hormone, cortisol, in an 
animal species (Satterlee et al., 1989) and humans (Brody et al., 2002).  
 The numerous effects of Vitamin C in the brain including preventing oxidative stress, 
neurotransmitter synthesis and modulation, neural maturation, and its effects on stress 
hormones and potentially neurogenesis suggest that vitamin C may be a potent anxiolytic with 
cognitive enhancing properties. 
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1.7 The Current study 
 The planned research was intended to determine whether a broad-spectrum 
micronutrient supplement (Berocca) has greater benefits than a single micronutrient 
supplement in decreasing anxiety-related behaviour and improving short-term memory in 
healthy rats. A number of studies have investigated the effects of single nutrient 
supplementation in psychiatric disorders finding only modest improvements (Rucklidge & 
Kaplan, 2013). Vitamin C alone has however been shown to significantly improve anxiety 
symptoms in rats (Hughes et al., 2011) and humans (Brody et al., 2002).  B-vitamin 
combinations (Stough et al., 2011; Lewis et al., 2013) as well as the broad-spectrum 
micronutrient supplement Berocca (Carroll et al., 2000; Kennedy et al., 2010) have also been 
shown to be effective in reducing stress and anxiety in humans. Therefore it is important to 
determine whether these benefits can be attributed to a single vitamin or vitamin group, to 
assess which micronutrients should be considered in the treatment of anxiety.  
 The current study also investigated whether a higher dose of Berocca is more effective 
in reducing anxiety symptoms. The recommended dose of one tablet per day has been shown 
to be useful in reducing stress and anxiety in humans (Carroll et al., 2000; Kennedy et al., 
2010). Both B vitamins (Stough et al., 2011) and vitamin C (Hughes et al., 2011) have been 
shown to produce beneficial effects on stress or anxiety symptoms at doses higher than in the 
Berocca formulation. This will be useful in recommending appropriate supplementation and 
dosage for stress and anxiety. It may also help to determine further avenues of research in this 
area, such as whether deficiencies in a number of micronutrients or a single micronutrient 
contribute to anxiety related behaviour. Rats received 8 weeks of supplementation with a 
broad-spectrum micronutrient supplement (Berocca), or a B vitamin complex supplement or 
vitamin C alone, and were examined through several behavioural measures of anxiety and one 
of short-term memory. 
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2.0 Aims and hypothesis: 
 Given the growing body of research investigating the effects of micronutrients on 
mental health in human populations, there is a need for animal research in the area. This will 
provide preclinical data, and may allow investigations into proposed mechanisms of action of 
micronutrient supplementation, as well as the use of techniques unavailable to human 
research. To date the main focus of micronutrient research has been on clinical human 
populations. Therefore research investigating the effects of micronutrient supplemenation on 
emotionality and cognition in animals is needed to guide future research in this area. The 
current study was a pilot study with two main aims: 
1. To determine whether a broad-spectrum micronutrient supplement (Berocca) has 
greater benefits than a single nutrient supplement (Vitamin C) in decreasing 
anxiety-related behaviour and improving short-term memory in rats. Having a B 
vitamin complex group allowed investigation into whether there was an additive 
effect of B vitamins with Vitamin C. This was important as the Berocca formula is 
made of a combination of B vitamins and vitamin C.  
2. To investigate whether a higher dose of Berocca, than has been previously used, is 
more effective in reducing anxiety symptoms. This will help to determine 
appropriate supplementation and dosage for stress and anxiety. 
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3.0 Method: 
 
3.1 Subjects: 
 Subjects of the present study were 80 (40 male and 40 female) PVG/c hooded rats 
from the breeding colony in the Psychology Department, University of Canterbury, 
Christchurch, New Zealand. Animals came in two cohorts. The first cohort of forty of the rats 
(20 male and 20 female) were born on the 8/3/2014, the other forty (20 male, 20 Female) were 
born on the 24/3/2014. These rats were weaned on post-natal day (PND) 30 and housed in 
same-sexed pairs in plastic 560 × 350 × 215-mm (length × width × height) cages. Each cage 
was divided in half by a 215-mm-high wire mesh partition that physically separated the two 
occupants but enabled them to see, smell and hear each other thereby minimizing any 
deleterious effects of social isolation. All rats were provided with their own drinking bottle 
and ad libitum food, and were kept in 12-h light: 12-h dark conditions with an ambient 
temperature of 20 ± 1 °C. All procedures were approved by the University of Canterbury 
Animal Ethics Committee. 
 Records of each rat’s normal daily intake of water were kept for 10 days to enable 
estimation of the quantities of each vitamin that needed to be added to ensure that each rat in a 
specific group was given access to the same concentration. On the 3/10/2014 rats were 
randomly separated into four experimental groups, each made up of 10 males and 10 females, 
with a total of 20 animals in each group, shown in Table 1. 
Table 1: Showing distribution of animals by sex within each treatment goup. 
Sex Control Berocca Vitamin C B Vitamins 
Males 10 10 10 10 
Females 10 10 10 10 
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 The number of rats of each sex in each treatment condition was sufficient to enable 
meaningful statistical calculation of the main effects of the vitamin treatment, and also 
calculation of sex x treatment interactions for each behavioural measure.  The latter set of 
calculations is very important because of sex differences in responsiveness to various 
experimental manipulations. 
 Each group received a different vitamin treatment (B vitamins, vitamin C, Berocca or 
control), delivered in their drinking water. On the 3/10/2014 vitamin treatment began, with the 
start of treatment for each group being separated by a week. The first group (n=20) to begin 
treatment was the B vitamin group. The second group (n=20) was Vitamin C. The third (n=20) 
was Berocca and the fourth (n=20) was control. Animals were treated for seven weeks with 
behavioural testing taking place in the eighth week. Treatment was continued while rats were 
being tested. Measurements of the volume of fluid drunk were made twice a week when they 
were replaced with fresh solutions.  This enabled calculation of approximate daily doses 
consumed during the 7 weeks of pre-test treatment and the time involved for behavioural 
testing.   
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3.2 Vitamin treatment procedure and rationale for micronutrient use and dosage: 
 
 Three different micronutrient treatments (B vitamin complex, Vitamin C and Berocca) 
and a control were used in the current study. The B vitamin complex and vitamin C were in 
powder form. The Berocca was an effervescent tablet. The B vitamin complex was made up in 
the lab from a combination of individual B vitamins to obtain the desired dose of each. 
 Records of each rat’s normal daily intake of water were kept for 10 days prior to 
treatment to enable estimation of the quantities of each vitamin that needed to be added to 
ensure that each rat in a specific group was given access to the same concentration. The 
average fluid intake and bodyweights for male and female rats were used to calculate the 
appropriate dosages. All vitamins were administered through the animals’ drinking water. This 
involved dissolving the following quantities of vitamins in the rats’ drinking water to achieve 
the desired target doses. The Berocca was administered a dosage equivalent to two tablets a 
day for a human. The B vitamin complex group was administered a dosage of only the B 
vitamins in the Berocca formula equivalent to two tablets per day for a human. The Vitamin C 
group was administered a dose of 81.6 mg/kg/day which is equivalent to a human consuming 
1000mg of Vitamin C per day via 2 tablets of Berocca i.e., 13.23mg/kg/day.the equivalent of 
1000mg of Vitamin C per day for a human. The exact dose of each of each individual 
micronutrient administered to each treatment group is shown in Table 2. This table also shows 
the quantities of each micronutrient in the previously established therapeutic dose of Berocca 
(one tablet per day for a human) (Carroll et al., 2000; Kennedy et al., 2010). All control rats 
were provided with unadulterated water. The concentrations of male and female vitamin 
solutions were different because the females drank more water relative to their bodyweight 
(i.e., females had a weaker solution than males). The dose/kg for both sexes was the same.  
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Table 2:  Composition of micronutrient treatments comparing equivalent human therapeutic 
dose for Berocca (1 tablet per day), double therapeutic dose for Berocca (2 tablets per day), B 
vitamin complex and vitamin C. 
Micronutrient Berocca 
Therapeutic dose (1 
tablet/ day) 
Berocca Treatment 
Group 
Double Therapeutic 
dose (2 tablets/day) 
B vitamin Complex Vitamin C 
B1 (Thiamine) 15 mg 30 mg 30 mg - 
B2 (Riboflavin) 15 mg 30 mg 30 mg - 
B3 (Nicotinamide) 50 mg 100 mg 100 mg - 
B5 (Panthenoic acid) 23 mg 46 mg 46 mg - 
B6 (Pyridoxine) 10 mg 20 mg 20 mg - 
B12 (Cyanocobalamin) 10 µg 20 µg 20 µg - 
C (Ascorbic Acid) 500 mg 1000 mg - 1000mg 
H (Biotin) 150 µg 300 µg - - 
B9 (Folic acid) 400 µg 800 µg - - 
Calcium 100 mg 200 mg - - 
Magnesium 100 mg 200 mg - - 
Zinc 10 mg 20 mg - - 
  
 
 Measurements of the volume of fluid drunk were made twice a week when they were 
replaced with fresh solutions.  This enabled calculation of approximate daily doses consumed 
during the 7 weeks of pre-test treatment plus the time involved for behavioural testing.  
Treatment was continued while the rats were being tested. 
 All rats were housed in pairs in large cages (as described in 3.1) and provided with 
their own food and water supply.  Therefore, it was possible to measure the volume of fluid 
drunk by individual rats thereby enabling calculation of individual vitamin dose consumed.  
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 The rationale for dosages relates to effective therapeutic doses previously found in 
animal and human studies. Recent research has investigated the benefits of single and broad-
spectrum micronutrient supplementation in psychiatric disorders. Vitamin C alone has been 
shown to significantly improve anxiety symptoms in rats (Hughes et al., 2011) and humans 
(Brody et al., 2002).  B-vitamin combinations (Stough et al., 2011; Lewis et al., 2013) as well 
as the broad-spectrum micronutrient supplement Berocca (Carroll et al., 2000; Kennedy et al., 
2010) have also been shown to be effective in reducing stress and anxiety in humans. The 
recommended dose of one Berocca tablet per day has been shown to be useful in reducing 
stress and anxiety in humans (Carroll et al., 2000; Kennedy et al., 2010). Both B vitamins 
(Stough et al., 2011) and vitamin C (Hughes et al., 2011) have been shown to produce 
beneficial effects on stress or anxiety symptoms at doses higher than in the Berocca 
formulation.  
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3.3 General procedure and behavioural testing apparatus: 
 
 Once normal daily intake of water was determined, estimation of the quantities of each 
vitamin that needed to be added to ensure that each rat in a specific group was given access to 
the same concentration were be made. Rats were then treated with vitamins for 7 weeks. 
Observations of the rats’ behaviour at the end of the treatment period involved four tests of 
anxiety-related behaviour i.e., emergence latency and open field activity, responsiveness to 
brightness change (Y-Maze), and elevated plus maze. The responsiveness to brightness change 
Y-Maze was also used to test short term memory by examining the time spent in a novel 
changed arm following an acquisition trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
8/3/2014 
 
Cohort 1 born  
24/3/2014 
 
 Cohort 2 born 
12/9/2014- 
19/9/2014 
 
 
Fluid (water) intake recorded for all rats 10 days. Initial bodyweight recorded for all 
rats. Dosage calculated for each treatment condition. 
 B vitamin Vitamin c Berocca Contol 
3/10/2014 
 
Tx begins    
10/10/2014 
 
 Tx begins   
17/10/2014 
 
  Tx begins  
24/10/2014 
 
   Tx begins 
     
17/11/2014 
-23/11/2014 
 
Behavioural 
Testing 
   
24/11/2014 
-30/11 2014 
 
 Behavioural 
Testing 
  
1/12/2014 
-7/12/2014 
 
  Behavioural Testing 
 
 
8/12/2014 
-14/12/2014 
 
   Behavioural Testing 
 
Figure 1. Timeline showing when each cohort began treatment and when each treatment 
group underwent behavioural testing. 
 
 Tests were conducted every second day over a period of 8 days. This allowed a 
minimum of 48 hours between tests for each rat. Each day 15 rats from a specific treatment 
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group were tested. As each group began treatment at different times the order of group testing 
was: B-vitamins, vitamin C, Berocca, Control. 
 The tests were carried out in the same experimental room, which maintained a stable 
temperature of 22 ̊C ± 2 ̊C with humidity control of 48% ± 10%. All tests were carried out 
between 9.00 and 15.00 hours in the light phase of the rats’ normal light/dark cycle. Over each 
eight-day testing period, each animal completed the emergence latency and open field tests 
once, the elevated-plus maze test once and the responsiveness to brightness in a Y-maze test 
once. The order of the tests was varied in a non-systematic way for individual rats. Each 
animal completed one test per day. 
 
3.3.1 Emergence latency and open-field activity: 
 The emergence portion of this test is used to assess anxiety or fearfulness, whereas the 
open field portion enables assessment of activity and emotionality. The emergence latency 
acts as a light-dark preference box test and is based on the rats’ innate avoidance of brightly 
illuminated open areas (Hascoët & Bourin, 2009; Sanchez, 1996). Higher emotionality, thus 
anxiety, is indicated by the tendency to avoid the light side (Hughes et al., 2004; Hascoët & 
Bourin, 2009). Once in the open field, location and behavior were measured to assess activity 
and emotionality, with higher anxiety indicated by less time in the centre squares and specific 
patterns of exploratory behavior (Cryan & Sweeny, 2011). The open field test is designed to 
elicit anxiety by separating the animal from its home cage and placing it in an inescapable 
novel environment (Prut & Belzung, 2002; Walsh & Cummings, 1976). The test was 
originally developed to measure emotionality in rats by Hall (1934) and now is one of the 
most widely used measures of anxiety-like behaviours on animal studies (Prut & Belzung, 
2002). As well as being used to measure anxiety-like behaviours, it has also been used to 
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demonstrate the behaviourally stimulant and sedative properties of drugs in animals (Gould et 
al., 2009). 
 For the emergence latency test, each rat was placed in a small, darkened start box dark 
side for 1 minute. Then, a slide separating the dark box from a 600 x 600 x 250mm dimly lit 
open field was withdrawn to allow the rat free access to the field. The time taken for the rat to 
emerge into the open field fully (all four paws) was recorded using a hand held stopwatch. If 
the rat did not emerge from the dark side after five minutes the trial was terminated. Rats that 
did not emerge were excluded from emergence latency and open field data analyses.  
 In this study, the open field apparatus consisted of a wooden open field measuring 600 
x 600 x 250mm which was placed on a table 700mm high. The floor was painted flat black 
and divided into a 4 x 4 grid of sixteen identical squares each measuring 150 x 150 mm. There 
were twelve peripheral squares and four central squares. The wooden walls were also painted 
black and were 250mm high. Garau et al. (2000) suggested that uncertainty (therefore anxiety) 
is increased by placing an animal in a novel environment and also by altering light levels. In 
this study, the light level was low (45 lux) and the testing area was unfamiliar to the animals 
producing low to moderate anxiety (File & Seth, 2003). An infrared camera was mounted on a 
single wooden arm 850mm above the open field and this was connected to a television 
monitor in the same experimental room which was used by the observer to monitor the 
animal’s position and behaviour within the open field.  
 Once in the open field it was noted which square the rat was located in every three 
seconds, for 5 minutes with the slide between the field and the start box closed.  It was also 
noted whether the rat was rearing up on its hind legs, walking or grooming itself. At the end of 
the trial the number of faecal boluses left in the apparatus were counted. This test and the 
behaviours that are observed are designed to provide a measure of general activity and 
emotional reactivity in animals (Hall, 1934a; Royce, 1977; Walsh & Cummings, 1976).  
 49 
 The total number of faecal boluses was also recorded as defecation increases when the 
animals are under stress. In this experiment, grooming was defined as the touching of front 
paws to mouth, paws to ears, mouth to sides, mouth to tail, mouth to feet, mouth to genitals, 
mouth to abdomen, feet to head/ears and feet to sides (Mayaho et al., 1995; Pleskacheva, 
1995). The number of times the animal was located in a different square to where it had been 3 
seconds prior was also calculated to indicate the number of transitions the animal made and to 
provide a measure of locomotor activity (ambulation). As it has been argued that animals 
prefer the outer squares to the exposed central squares (Prut et al., 2002), the total frequency 
of centre and corner square occupation was calculated. After each trial the dark box and open 
field were washed with Paraquat Blue 20% solution. 
 
3.3.2 Elevated plus-maze test: 
 The elevated plus maze creates an approach-avoidance conflict by placing rats a novel 
environment that also stimulates a natural aversion for height and open spaces (Kumar et al., 
2013; Salum et al., 2003). The open arms are considered to be more aversive than the closed 
arms (Cryan & Sweeney, 2011) and it is thought that a less anxious animal will explore open 
arms more. This has been shown with anxiolytic drug treatment increasing both entries into 
and time spent in open arms, while anxiogenic dugs do the opposite (Braun et al., 2011; 
Handley & Mithani, 1984; Hogg, 1996; Lister, 1987; Moser et al., 1990; Pellow et al., 1985). 
 In this study, a four-armed plus maze was used of which two arms were open (clear 
Perspex walls), and the other two were closed (wooden walls). The whole maze is elevated 1m 
above the floor. The light level was low (45 lux) and the testing arena was unfamiliar to the 
animals producing low to moderate anxiety (File & Seth, 2003). An infrared camera was 
mounted above the elevated plus maze and this was connected to a television monitor in the 
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same experimental room, which was used by the observer to monitor the animal’s position and 
behaviour within the open field.  
 Individual rats were removed from their home cage and placed into the centre of the 
maze facing one of the closed arms. Every three seconds for 5 minutes the arm the rat was 
occupying was recorded. The number of entries into each arm was also recorded thereby 
enabling calculation of preferences for entering and occupying open versus closed arms. 
Exploratory behaviours rearing, walking and grooming were also recorded and it was noted in 
which arm these behaviours were exhibited. The primary indices of anxiety in the elevated 
plus maze are the percentage of entries and time spent in open arms (Salum et al., 2003). The 
total number of entries into both arms is a reliable measure of motor activity, since it is little 
affected by anxiety (Cruz et al., 1994; Salum et al., 2003). The maze was washed down and 
disinfected with 20% Paraquat Blue after each animal. 
 
3.3.3 Responsiveness to brightness in a Y-maze: 
 This test was used to assess short-term spatial memory and curiosity. It also exploits 
the rats’ natural tendency to explore novel areas. It is thought that a less anxious animal will 
enter the novel arm more often than the familiar arm, whereas a more anxious animal will 
show a preference for familiarity rather than novelty (Hughes, 2001; Hughes & Neeson, 2003; 
Samyai et al., 2000).  
 In this study, a wooden apparatus was placed on a table 700mm high which was 
illuminated overhead by low (45 lux) fluorescent lighting 1390mm above the maze. An 
infrared video camera was mounted 1390mm directly above the apparatus. This was used by 
the experimenter to monitor the rats’ location within the maze. The arms of the maze were 
450mm long with a 120 ̊ angle between them. The stem of the maze was 300mm long with a 
black compartment at the base, which was separated from the rest of the stem by a guillotine 
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slide. Both the stem and arms were 100mm wide and 140mm high. One arm contained a black 
painted metal insert while the other contained a white painted metal insert which occupied the 
width, height and 400mm length of each arm. A clear Perspex lid covered the entire apparatus.  
 Each animal experienced an acquisition and retention trial. Each animal was placed in 
the black compartment at the base of the stem and then released. It was allowed to roam freely 
within the maze for 5 minutes. This is known as the acquisition trial. During this trial one arm 
contained a black insert while the other arm contained a white insert. After 5 minutes the 
animal was returned immediately to its home cage where it had free access to food and water. 
The inserts were replaced with two clean black inserts and the entire apparatus was wiped 
down and disinfected with 20% Paraquat Blue solution. The rat was then allowed access to the 
maze again for a 3-min retention trial during which it was faced with two black arms, one of 
which had changed from white to black i.e., the novel arm. Every 3 seconds it was noted 
which arm the rat was occupying, and how often each was entered. It was therefore possible to 
subsequently calculate the percentage of entries into and time spent in the changed novel arm, 
as well as the total entries of both arms. This information enabled calculation of the rats’ 
preferences for the changed versus unchanged arm (and thus curiosity/anxiety, and memory 
for which arm has changed). 
 During the acquisition trial, one half of the animals (n = 40) experienced the maze with 
the black insert in the left arm while the remaining half experienced it with the black insert in 
the right arm. It was randomly determined which side the black insert would be on for each 
animal. Within each treatment group ten rats (five male, five female) completed the maze with 
the black insert on the left and ten rats (five male, five female) completed it with the black 
insert on the right. The entire apparatus was wiped down and disinfected with 20% Paraquat 
Blue solution at the end of the retention trial. 
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3.4 Rationale for Behavioural apparatus: 
 The current study used four empirically supported behaviour tests. Three were of 
unconditioned anxiety-like behaviour; emergence latency (light-dark box) in an open field, the 
open field test and an elevated plus maze. The Y-maze was used to examine spatial working 
memory, and it has also been shown to be useful for assessing anxiety (Aitchison & Hughes, 
2006).  
 The emergence latency (light-dark), open field and elevated plus maze tests play on the 
conflicting drives of avoidance an exploration of a perceived threatening stimulus (i.e. an open 
space or lit area) (Crawley, 1985; Hascoët & Bourin, 2003; Montgomery, 1955; Salum et al., 
2003). When a rat is confronted with novelty, its behaviour is determined by this conflict 
between its drive to explore the unknown area and its motivation to avoid potential danger 
(Ohl, 2003). This approach-avoidance conflict is assumed to represent anxiety (Ennaceur, 
2014).  
 The open field and elevated plus maze also assessed rearing and grooming behaviours 
inside the apparatus. Rearing is an exploratory behaviour (Carli et al., 1989; Espejo, 1997) and 
is used as an indicator of anxiety in the open field (Carli et al., 1989; Lamprea et al., 2008), 
and the elevated plus maze (Escorihuela et al., 1999; Lepicard et al., 2001; Rodgers & Dalvi, 
1997). Reductions in rearing are thought to indicate heightened anxiety in the animal (Belzung 
& Griebel, 2001; Rodgers et al., 1997). Grooming is considered to be an adaptation to stressful 
situations and conflict (Espejo, 1997; Hannigan & Isaacson, 1981; Kalueff & Tuohimaa, 2004; 
Kametani, 1988; Torres, 1961). Stressors such as exposure to a novel environment, handling, 
and immersion in water, increase grooming in rats (Eguibar & Moyaho, 1997; Van Erp et al., 
1994). Anxiolytic drugs have been shown to decrease grooming (Barros et al., 1994). 
Therefore an increase in grooming behaviour is thought to be a valuable tool for assessing 
heightened anxiety in animals (Nin et al., 2012). 
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 The emergence latency test in the open field serves as a form of light-dark box test. In 
this test it is thought the light compartment (open field) is more aversive than the dark 
compartment (Cryan & Sweeney, 2011). Therefore the more anxious an animal is, the longer 
its latency to emerge from the dark compartment into the open field compared to an animal 
experiencing lower anxiety levels (Hascoët et al., 2000). Numerous studies have shown 
anxiolytic drug treatment increases the number of entries into the light compartment, the time 
spent in the light compartment, and reduces freezing behaviour (Crawley & Goodwin, 1980; 
De Angelis & Furlan, 2000; Hascoët et al., 2000; Hascoët & Bourin, 2003; Jones et al., 1988). 
 In the open field tests rodents have a preference for the periphery of the apparatus over 
central parts (Prut & Belzung, 2003). The avoidance of unprotected areas is used as an 
indicator of anxiety (Ohl, 2003). The more anxious an animal is, the more time it will spend in 
the corners of the apparatus and less time in the centre squares (Hall, 1934; Prut & Belzung, 
2003). Rearing and grooming behaviours are also observed and it is thought that a more 
anxious animal will display less rearing and more grooming (Ohl, 2003; Prut & Belzung, 
2003). An increase in defication is indicative of an increase in anxiety (emotional stress) (Hall, 
1934; Wills et al., 1983). Therefore the number of fecal boluses left by each rat in the field 
was recorded. 
 The elevated plus maze is based on creating an approach-avoidance conflict between 
curiosity and exploration of a novel environment and rodents’ natural aversion for height and 
open spaces (Kumar et al., 2013; Salum et al., 2003). The open arms are considered to be more 
aversive than the closed arms (Cryan & Sweeney, 2011). Therefore rats will typically enter the 
closed arms more frequently and spend more time in them compared to the open arms (Salum 
et al., 2003). A less anxious animal will show greater exploration of the open arms. This has 
been shown with anxiolytic drug treatment increasing both entries into and time spent in open 
arms, while anxiogenic drugs have the opposite effect (Braun et al., 2011; Handley & Mithani, 
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1984; Hogg, 1996; Lister, 1987; Moser et al., 1990; Pellow et al., 1985). The primary indices 
of anxiety in the elevated plus maze are the percentage of entries and time spent in open arms 
(Salum et al., 2003). The total number of entries into both arms is a reliable measure of motor 
activity, since it is little affected by anxiety (Cruz et al., 1994; Salum et al., 2003). 
 The Y-maze is a well-known test of spatial working memory in rats (Kumar et al., 
2013), that is based on the tendency of rodents to explore novel environments (Dellu et al., 
2000; Ma et al., 2007). Responsiveness to brightness change in a Y-maze has been shown to 
be a useful index of curiosity-motivated spatial working/short term memory (Hughes, 2004; 
Hughes & Maginnity, 2007; Hughes & Neeson, 2003). Following an acquisition trial the 
number of entries and time spent in the changed arm are used to indicate memory 
performance. Rats that make more entries into and spend more time in the changed (novel) 
arm are thought to have a better short term memory compared to those that spend more time in 
the unchanged arm. This is because the rats must remember the nature of both arms in order to 
identify the one that has been changed. If the animals recognise which arm has been changed 
they are more likely to make more entries and spend more time in it due to their tendency to 
approach and explore novel stimuli. The Y-maze can also be used to assess anxiety-like 
behaviour. Activity in the Y-maze is inversely related to anxiety (Archer, 1973). It is thought 
that higher levels of emotional reactivity (anxiety) result in fewer changed arm entries and 
occupation. Higher levels of anxiety result in the animal being less inclined to explore the 
novel environment. Therefore, they make fewer entries and spend less time in the changed arm 
because they have a preference for a familiar environment over a novel environment. This can 
occur with anxiogenic experiences in other situations (Aitchison & Hughes, 2006; Aitken, 
1974; Hughes, 1987; Misslin & Ropartz, 1981). 
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4.0 Statistical Analysis: 
 
 The main focus of this study was to examine the effects of receiving micronutrients on 
animal emotionality and whether this effect was maintained over time while receiving 
micronutrients as part of a normal diet.  
 All raw data sets were analysed using the statistical program Statistical Package for the 
Social Sciences (SPSS) 19.0. Each measure was treated to a separate 4 (treatment group) x 2 
(sex) factorial ANOVA. Fischer LSD post hoc tests were carried out when a main effect was 
significant (p<.05). Sex differences were included in the analyses due to sex differences in 
brain maturation and in brain maturation rates (Anderson, 2003). Given male and female 
brains develop differently, receiving micronutrients, as part of their diet would likely affect the 
two sexes differently over time. Differences in behaviour at each testing age were investigated 
to detect any additional changes after receiving micronutrients over an extended period of 
time.  
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5.0 Results 
 
5.1 Fluid Intake, Dosage and Bodyweight 
 Each animal had their fluid intake recorded twice a week. Bodyweights were taken 
before and after treatment. This enabled the calculation of average dosage (mg/kg) for males 
and females in each treatment group. ANOVAs were used to assess the effects of 
micronutrient treatment, sex and any interactions on fluid intake, dosage consumed and 
bodyweight. 
 
Table 3: ANOVA results for fluid intake (mL/100g/day) and final bodyweight for treatment 
group and sex. 
Treatment group F Df P 
Fluid intake (mL/100g/day) 28.98 3,120 .0001 
Final Bodyweight (g) 1.25 3,72 .298 
Sex F df P 
Fluid intake (mL/100g/day) 3235.39 1,120 .0001 
Final Bodyweight (g) 2788.97 1, 72 .0001 
 
5.1.1 Fluid intake: 
 The mean ± S.E.M (mL/100g) of fluid intake per day for rats in B vitamin, vitamin C, 
Berocca and control groups respectively were 8.87  ± .59, 9.03 ± .72, 10.44 ± .72, 9.61 ± .72. 
There was a significant main effect of sex on fluid intake, see Table 3. Females (13.24 ± .09) 
drank significantly more than males (5.74 ± .15). There was a significant main effect of 
treatment on fluid intake, see Table 3. Fischer post hoc tests revealed that the Berocca group 
drank significantly more than the B vitamin, vitamin C and control groups (all p < .0001). The 
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control group also drank significantly more than B vitamins (p < .0001) and vitamin C (p < 
.01) groups. Therefore it is important to note that only the Berocca group drank significantly 
more fluid per day than the control group. There was a significant interaction between sex and 
vitamin group, shown in Figure 2. The males in the B vitamin group drank almost the same 
amount of fluid per day as the control group. However females in the B vitamin group drank 
significantly less fluid than the control group. 
Figure 2: Mean ± S.E.M fluid intake (ml/100mg b.w./day) for males and females separately 
following exposure to B vitamins, Vitamin C, Berocca, or unadulterated drinking water 
(Control). 
∗ Significantly different (p<.05) from water control group for that particular sex. 
ab Groups with superscripts in common significantly different (P<.05) for that particular sex. 
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5.1.2 Dose: 
 The Berocca formula contains both vitamin C and all the B vitamins in the B vitamin 
formulation. The dosages of vitamin C and B vitamins Berocca was known prior to treatment. 
By measuring the dosage of Berocca it was possible to calculate the dosage of B vitamins and 
vitamin in Berocca that were consumed. The mean ± S.E.M dose per day (mg/Kg) of B 
vitamins alone, vitamin C alone, B vitamins in Berocca and vitamin C in Berocca, were 
respectively 18.92 ± .29, 85.23 ± 2.74, 25.98 ± .61, 114.95 ± 2.73. There was a significant 
main effect of sex on dose (see Table 4), with females consuming a significantly higher dose 
of vitamins than males. There was a significant main effect of treatment group on dose, see 
Table 4. Fischer LSD post hoc tests revealed that the Berocca group consumed significantly 
more B vitamins and vitamin C than the B vitamin and vitamin C group alone (all p < .0001). 
There was a significant interaction between sex and treatment group, shown in Figure 3. 
Females consumed a significantly higher dosage of vitamin C, vitamin C in Berocca, and B 
vitamins in Berocca, than males. However they did not consume a significantly higher dose of 
B vitamins alone, than males. 
 
Table 4: ANOVA results for dose (mg/kg/day) for treatment group and sex. 
Dose (mg/kg/day) F  Df P 
Treatment group 
 
1664.01 3,120 .0001 
Sex  154.72 1,120 .0001 
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Figure 3: Mean ± S.E.M dose (mg/kg b.w/day) for males and females separately following 
consumption of B vitamins alone, vitamin C alone, B vitamins in Berocca, and vitamin C in 
Berocca. 
ab Groups with superscripts in common significantly different (P<.05) for that particular sex. 
 
5.1.3 Final Bodyweight and comparison with pre-treatment bodyweight: 
 Animals were weighed before and after treatment. The pre-treatment bodyweights 
were taken before the animals were divided into treatment groups and are therefore an average 
for all animals and not for each individual treatment group.  The mean ± S.E.M final 
bodyweight (g) for rats in B vitamin, vitamin C, Berocca and control groups respectively were 
311.75 ± 20.54, 314.50 ± 23.19, 305.80 ± 21.49, 314.05 ± 22.63. There was a significant main 
effect of sex on bodyweight with males (406.05 ± 3.01) being significantly heavier than 
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females (217 ± 2.11), see Table 3. The main effect of treatment on bodyweight was not 
significant nor was the interaction between sex and treatment, see Table 3. 
 The mean ± S.E.M pre-treatment bodyweights (g) for males and females were 
respectively 375.85 ± 2.84 and 204.10 ± 1.78. When compared with the post-treatment 
bodyweights males gained significantly more weight than females. The pre-treatment 
bodyweights were significant less than the final bodyweights for all treatment groups (control, 
B vitamins, vitamin C and Berocca) (all p < .0001), shown in Figure 4. 
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Figure 4: Mean ± S.E.M final bodyweights for following treatment with unadulterated drinking 
water (control), B vitamins, Vitamin C, or Berocca, compared to pre-treatment bodyweight 
(pre-treatment b.w.), separately for male and female. 
∗ Significantly different (p<.05) from water control group for that particular sex. 
abc Groups with superscripts in common significantly different (P<.05) for that particular sex. 
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5.2 Emergence Latency and Open Field Tests 
 The emergence latency and open field tests were conducted consecutively. Each 
animal was tested once. After the animal emerged for the darkened box into the open field 
measures were taken for the open-field portion of the test. ANOVAs were used to assess 
whether there was an effect due to micronutrient treatment group, sex, and micronutrient x sex 
interactions. For the emergence latency and open field tests 28 rats were excluded from the 
analysis because they failed emerge. Seven were from the B vitamin group (2 male, 5 female), 
six male rats from the vitamin C group, six rats from the Berocca group (3 male, 3 female) and 
nine from the control group (5 male, 4 female). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63 
Table 5: Mean (± S.E.M) for responses in the open field test for control (n=11), B vitamins 
(n=13), vitamin C (n=14), Berocca (n=14) micronutrient treatment groups and for male 
(n=24) and female (n=28). 
Treatment 
Group 
Control B C Berocca F (3, 43) P 
Transitions 39.43 
(3.41) 
36.50 
(2.47) 
38.68 (3.42) 42.32 (2.22) .73 .542 
Center square 
occupancy 
5.00 (1.01) 3.76 (.85) 4.55 (1.11) 5.88 (1.83) .47 .706 
Corner square 
occupancy 
59.35 
(3.28) 
57.81 
(3.34) 
47.70 (4.38) 42.09 (3.48) 4.73 .006 
Walking 66.67 
(2.38) 
50.28 
(2.77) 
60.90 (2.72) 68.17 (2.65)  9.69 .0001 
Rearing 27.38 
(2.26) 
31.83 
(3.36) 
27.63 (3.03) 24.36 (2.24) 1.31 .285 
Grooming 2.0 (1.02) 7.63 (1.87) 5.25 (2.28) 5.74 (1.89) 1.41 .252 
Faecal boluses 1.00 (.55) 1.51 (.45) 1.73 (.44) 1.38 (.64) .36 .785 
Sex Male Female   F (1, 43) P 
Transitions 36.24 
(1.66) 
42.22 
(2.17) 
  4.23 .046 
Centre square 
occupancy 
4.36 (1.01) 5.23 (.79)   .43 .518 
Corner square 
occupancy 
51.64 
(3.30) 
52.44 
(2.60) 
  .133 .717 
Walking 60.55 
(2.79) 
62.46 
(1.81) 
  .52 .476 
Rearing 29.65 
(2.19) 
25.95 
(1.89) 
  1.79 .188 
Grooming 3.77 (1.04) 6.54 (1.49)   2.04 .160 
Faecal boluses 2.18 (.41) .63 (.25)   .81 .495 
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5.2.1 Emergence latency: 
 There was a significant main effect of sex on time (seconds) to emerge (F (1,43) = 
15.872, p < .001, partial η2 = .270), with females (112.987 ± 12.73) taking significantly longer 
to emerge than males (49.16 ± 9.43). The mean ± S.E.M time to emerge (seconds) for rats in B 
vitamin, vitamin C, Berocca and control groups respectively were 125.40 ± 25.12, 66.93 ± 
12.54, 65.63 ± 14.92, 66.33 ± 15.45. There was a significant main effect of vitamin group on 
emergence latency (F (3,43) = 3.5, p < .05, partial η2 = .196). Fischer LSD post hoc tests 
revealed the B vitamin group took significantly longer to emerge than the Berocca group (p < 
0.05), shown in Figure 5. The B vitamin group also took longer to emerge than the control and 
vitamin C groups but this was not statistically significant (p = .086 and .099 respectively). 
There was a non-significant interaction between sex and vitamin group on emergence latency 
(F (3,43) = .873, p = .463, partial η2 = .057). 
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Figure 5: Mean ± S.E.M of the mean emergence latency times (seconds) for treatment group. 
a Groups with superscripts in common are significantly different (P<.05). 
 
5.2.2 Transitions: 
 There was a significant main effect of sex on the number of transitions made, with 
females making significantly more transitions than males, shown in Table 5. The main effect 
of treatment group on the number of transitions was not significant nor was the interaction 
between sex and treatment group, shown in Table 5. 
 
5.2.3 Centre Square Occupancy: 
 The main effects of treatment group and sex on centre square occupancy were not 
significant. Nor was the interaction between sex and vitamin group, shown in Table 5. 
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5.2.4 Corner Square Occupancy: 
 There was a significant main effect of treatment group on corner square occupancy 
(see Table 5). Fischer LSD post hoc tests revealed that the Berocca group spent significantly 
less time in the corner squares than the B vitamin and control groups (both p < .01), shown in 
Figure 6. The vitamin C group also spent less time in corner squares than B vitamin and 
control groups but this was not statistically significant (p = .093 and .088 respectively). The 
main effect of sex on corner square occupancy was not significant, nor was the interaction 
between sex and treatment group (see Table 5). 
Figure 6: Mean ± S.E.M of the mean number corner squares occupied for treatment group. 
∗Significantly different (p<.05) from water control group. 
a Groups with superscripts in common are significantly different (P<.05). 
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5.2.5 Walking: 
 There was a significant main effect of vitamin group on time spent walking (see Table 
5). Fischer LSD post hoc tests showed the B vitamin group spent significantly less time 
walking than all other groups (all p < .001), shown in Figure 7. The vitamin C group also 
spent less time walking than the Berocca group but this was not statistically significant (p = 
.062). The main effect of sex on time spent walking was not significant nor was the interaction 
between sex and treatment group (see Table 5). 
 
Figure 7: Mean ± S.E.M of the mean time spent walking for treatment group. 
∗Significantly different (p<.05) from water control group. 
ab Groups with superscripts in common are significantly different (P<.05). 
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5.2.6 Rearing: 
 The main effects for treatment group and sex on time spent rearing were not 
significant. Nor was the interaction between gender and treatment group (see Table 5). 
 
5.2.7 Grooming: 
 The main effects of treatment group and sex on time spent grooming were not 
significant. Nor was the interaction between treatment group and sex (see Table 5). 
 
5.2.8 Faecal Boluses: 
 There was a significant main effect of sex on the number of faecal boluses, with 
females leaving significantly fewer boluses than males (see Table 5). The main effect of 
treatment group on number of faecal boluses was not significant, nor was the interaction 
between sex and treatment group on number of faecal boluses (see Table 5). 
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5.3 Elevated plus maze: 
 
In the elevated plus maze each animal was tested once. ANOVAs were used to assess whether 
there was an effect due to treatment group, sex differences, and treatment x sex interactions. 
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Table 6: Mean (± S.E.M) for responses in the elevated plus maze for control (n=20), B 
vitamins (n=20), vitamin C (n=20), Berocca (n=20) micronutrient treatment groups and for 
male (n=40) and female (n=40). 
 
 
 
Treatment Group Control B C Berocca F (3, 72) P 
% open arm entries 36.30 (3.34) 39.65 (4.76) 38.99 (3.72) 48.15 (3.37) 1.76 .163 
% closed arm 
entries 
63.69 (3.34) 60.69 (4.29) 61.01 (3.72) 52.59 (3.56) 1.62 .192 
% open arm 
occupancy 
36.30 (3.34) 39.65 (4.76) 38.99 (3.72) 48.15 (3.37) 1.76 .163 
% closed arm 
occupancy 
63.69 (3.34) 60.69 (4.29) 61.01 (3.72) 52.59 (3.56) 1.62 .192 
Total entries both 
arms 
77.15 (2.15) 77.55 (1.90) 76.00 (1.24) 75.70 (1.43) .27 .847 
Rearing open 11.80 (1.24) 11.55 (1.54) 10.15 (1.28) 15.05 (1.35) 2.26 .089 
Rearing closed 19.05 (1.15) 18.30 (1.60) 17.70 (1.18) 19.45 (1.32) .33 .805 
Walking open 16.75 (1.59) 18.05 (1.91) 19.30 (1.91) 21.20 (1.45) 1.23 .304 
Walking closed 28.30 (2.11) 23.10 (2.02) 23.90 (1.83) 19.15 (1.80) 3.89 .012 
Sex Male Female   F (1, 72) P 
% open arm entries 38.63 (3.22) 42.89 (2.18)   1.21 .275 
% closed arm 
entries 
61.56 (3.06) 57.44 (2.22)   1.19 .278 
% open arm 
occupancy 
38.63 (3.22) 42.89 (2.18)   1.21 .275 
% closed arm 
occupancy 
61.56 (3.06) 57.44 (2.22)   1.19 .278 
Total entries both 
arms 
75.05 (1.47) 78.15 (.78)   3.28 .075 
Rearing open 11.75 (1.12) 12.53 (.83)   .32 .576 
Rearing closed 18.63 (.91) 18.63 (.96)   .00 1.0 
Walking open 16.93 (1.29) 20.73 (1.10)   4.96 .029 
Walking closed 23.05 (1.69) 24.18 (1.15)   .349 .556 
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5.3.1 Percentage of entries into open arms: 
 The main effects of sex and treatment group on the percentage of entries into open 
arms were not significant. Nor was the interaction between sex and treatment group (see Table 
6). 
 
5.3.2 Percentage of entries into closed arms: 
 The main effects of sex and treatment group on the percentage of entries into closed 
arms were not significant. Nor was the interaction between sex and treatment group (see Table 
6). 
 
5.3.3 Percentage open arm occupancy: 
 The main effects of sex and treatment group on the percentage of open arm occupancy 
were not significant. Nor was the interaction between sex and treatment group (see Table 6). 
  
5.3.4 Percentage closed arm occupancy: 
 The main effects of sex and treatment group on the percentage of closed arm 
occupancy were not significant. Nor was the interaction between sex and treatment group (see 
Table 6). 
 
5.3.5 Total entries both arms: 
 The main effects of sex and treatment group on the total number of entries into both 
arms were not significant. Nor was the interaction between sex and treatment group (see Table 
6). 
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5.3.6 Rearing in open arms 
 The main effects of sex and treatment group on the time spent rearing in open arms 
were not significant. Nor was the interaction between sex and treatment group (see Table 6). 
 
5.3.7 Rearing in closed arms: 
 The main effects of sex and treatment group on the time spent rearing in closed arms 
were not significant. Nor was the interaction between sex and treatment group (see Table 6). 
 
5.3.8 Walking in open arms: 
 There was a significant main effect of sex on time spent walking in open arms, with 
females spending significantly more time than males walking in open arms. The main effect of 
treatment group on time spent walking in open arms was a not significant, nor was the 
interaction between sex and treatment group (see Table 6). 
 
5.3.9 Walking in closed arms: 
 There was a significant main effect of treatment group on time spent walking in closed 
arms (see Table 6). Fischer LSD post hoc tests revealed the Berocca group spent significantly 
less time walking in closed arm then control (p < .001), shown in Figure 8. The Berocca group 
also spent less time walking in closed arms than vitamin C but this was not statistically 
significant (p = .082). The main effect of sex on time spent walking in closed arms was not 
significant, nor was the interaction between sex and treatment group (see Table 6). 
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Figure 8: Mean ± S.E.M of the mean time spent walking in closed arms for treatment group. 
∗ Significantly different (p<.05) from water control group. 
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5.4 Responsiveness to Brightness Change in a Y-maze: 
 
 In the Y-maze each animal was tested once. ANOVAs were used to assess whether 
there was an effect due to micronutrient treatment group, sex differences, and treatment x sex 
interactions. 
 
Table 7: Mean (± S.E.M) for responses in responsiveness to brightness in Y-maze test (n=20), 
B vitamins (n=20), vitamin C (n=20), Berocca (n=20) micronutrient treatment groups and for 
male (n=40) and female (n=40). 
Treatment Group Control B C Berocca F (3, 72) P 
% change arm 
entries       
47.16 (1.15) 47.66 
(7.26) 
48.31 
(4.97) 
62.21 (2.55) 2.91 .04 
% change arm 
occupancy 
37.71 (2.52) 50.63 
(8.01) 
58.82 
(5.27) 
66.29 (3.54) 5.96 .001 
Total entries both 
arms 
6.10 (.42) 3.30 (.64) 5.00 (.72) 5.75 (.45) 6.27 .001 
 
Sex Male Female   F (1, 72) P 
% change arm 
entries       
48.51 (4.25) 54.16 
(2.08) 
  1.76 .189 
% change arm 
occupancy 
47.62 (4.79) 56.10 
(2.88) 
  3.13 .081 
Total entries both 
arms 
3.85 (.43) 6.23 (.34)   22.78 .0001 
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5.4.1 Percentage Change arm Entries: 
 There was a significant main effect of treatment group on percentage of change arm 
entries (see Table 7). Fischer LSD post hoc tests revealed the Berocca group had significantly 
higher change arm entry percentage than all other groups (all p < 0.05). There was no 
significant difference in change arm entry percentage between all other groups. The main 
effect of sex on percentage of change arm entries was not significant (see Table 7). 
 There was a significant interaction between sex and treatment group on the percentage 
of change arm entries, shown in Figure 9. This effect indicated males and females may be 
affected differently by vitamin treatment. Specifically, percentage of change arm entries for 
males was increased with Berocca treatment but decreased by B vitamin treatment. However 
for females the response was different. Both Berocca and B vitamin treatment increased 
percentage of change arm entries compared to control, for females. 
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Figure 9: Mean ± S.E.M percentage change arm entries for males and females separately 
following treatment with B vitamins, vitamin C, Berocca, or unadulterated drinking water 
(control). 
∗Significantly different (p<.05) from water control group for that particular sex. 
a Groups with superscripts in common significantly different (P<.05) for that particular sex. 
 
5.4.2 Percentage Change Arm Occupancy: 
 There was a significant main effect of treatment group on percentage change arm 
occupancy (see Table 7). Fischer LSD post hoc tests revealed that the Berocca group spent 
significantly more time in the change arm than the B vitamin and control groups (p < 0.05). 
Berocca also spent more time in the change arm than the vitamin C group, but this was not 
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statistically significant (p = 0.051). The main effect of sex on percentage change arm 
occupancy was not significant (see Table 7).  
 There was a significant interaction between sex and vitamin group on percentage 
change arm occupancy, shown in Figure 10. This effect indicates males and females may be 
affected differently by vitamin treatment. Specifically, percentage of change arm occupancy 
for males was increased with Berocca treatment but decreased by B vitamin treatment. 
However for females the response was different. Both Berocca and B vitamin treatment 
increased the percentage of change arm occupancy compared to control, for females. 
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Figure 10: Mean ± S.E.M percentage change arm occupancy for males and females separately 
following treatment with B vitamins, vitamin C, Berocca, or unadulterated drinking water 
(control). 
∗Significantly different (p<.05) from water control group for that particular sex. 
a Groups with superscripts in common significantly different (P<.05) for that particular sex. 
 
5.4.3 Total Entries into both arms 
 There was a significant main effect of vitamin group in the total number of entries into 
both arms (see Table 7). Fischer LSD post hoc tests revealed the B vitamin group made 
significantly fewer total entries into both arms than all other groups (all p < 0.05), shown in 
Figure 11. There was a significant main effect of sex on the total number of entries into both 
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arms, with females making more entries into both arms compared to males. The interaction 
between sex and vitamin group was not significant (see Table 7). 
 
Figure 11: Mean ± S.E.M total number of entries into both arms for treatment group. 
∗Significantly different (p<.05) from water control group. 
ab Groups with superscripts in common significantly different (P<.05) 
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6.0 Discussion of results:  
 
 In the current study, 80 rats were divided into four treatment groups each with a 
different micronutrient treatment administered through their drinking water. Treatment groups 
consisted of a B vitamin group, a vitamin C group and a broad-spectrum micronutrient group 
(Berocca, B + C), and a control group (unadulterated water). Dosages used were determined to 
be at a therapeutic level, based on previous studies (Hughes et al., 2011), and above 
therapeutic levels to investigate whether a higher dose (B vitamins and Berocca) may have 
greater benefits or a negative effect. Each treatment group received vitamin treatment for 
seven weeks and remained on treatment during testing which occurred on the 8th week of 
treatment. Three behavioural tests of anxiety related behaviour (emergence latency, OFT, 
EPM) and one of short term spatial memory (responsiveness to brightness change in a Y 
Maze) were used to assess the effects of micronutrient supplementation on anxiety-like 
behaviour and memory. Male and female rats were used to allow for possible sex differences 
in the effects of vitamin treatment. Conclusions were then drawn from any significant results 
about the behavioural outcomes of different micronutrient supplements over a prolonged 
period (chronic supplementation). 
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6.1 Summary of results 
 The results revealed a number of significant behavioural differences between treatment 
groups. The rats receiving broad-spectrum supplementation (Berocca) showed significantly 
less emotionality and significantly improved short-term spatial memory when compared to 
other treatment groups. Sex differences were found quite often as well as interactions between 
sex and treatment group especially in the Y maze.  
 The B vitamin group was the slowest to emerge in the emergence latency test with 
Berocca being significantly faster, but not than other groups. Females also took longer to 
emerge than males. In the OFT the Berocca group spent significantly less time in the corner 
squares than B vitamin and control groups, suggesting lower anxiety levels than these groups. 
The Y maze revealed the greatest number of significant differences between treatment groups. 
The Berocca group had a significantly higher percentage of entries into and occupancy of the 
changed arm, as well as total entries of both arms (ambulation) than all other treatment groups. 
In the Y maze there was also a significant sex difference in ambulation, with females making 
more entries into both arms than males. There were significant sex x treatment interactions in 
change arm entries and occupancy suggesting different treatments affected each sex 
differently. The most notable interactions here were differences in the effects of B vitamin and 
Berocca supplementation on males and females. Specifically, the percentage of change arm 
entries and occupancy for males was increased with Berocca treatment but decreased by B 
vitamin treatment. However for females the response was different. Both Berocca and B 
vitamin treatment increased the percentage of change arm occupancy compared to control, for 
females. Nothing of major significance was found in the EPM.  
 These results provide evidence that a broad-spectrum of micronutrients may be more 
effective than a single micronutrient or vitamin group in reducing anxiety-related behaviour 
and improving memory in a normal rat population. The sex x treatment interactions also 
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suggested that certain micronutrient treatments may be more appropriate for different sexes. 
Also, it was noteworthy that the Berocca group consumed on average a significantly higher 
dose of both B and C vitamins than the two other treatment groups. 
 
6.1.1 Dose and Fluid intake:  
 Fluid intake and doses were higher for females among all treatment groups. The 
Berocca group also drank significantly more than all other groups (possibly due to a better 
taste of the solution) and accordingly ingested a significantly higher dose of B vitamins than 
the B vitamin group, and a higher dose of vitamin C than the vitamin C group. This may have 
affected the behavioural results. It is possible that both the B and C groups’ doses were at a 
sub-therapeutic level, which would explain the effects due to Berocca (a combination of B and 
C) but not the single vitamins. This may be true for vitamin C, as high doses of this vitamin 
have been shown to have an anxiolytic effect in rats (Hughes et al., 2011). These results make 
it difficult to determine exactly whether the anxiolytic effects were due to higher dose of a 
single vitamin group in the Berocca, or to a synergistic effect of the combination of B 
vitamins, vitamin C and minerals. 
 
6.1.2 Treatment effects: 
 In the emergence latency into an open field test, the B vitamin group took significantly 
longer to emerge than the Berocca group, suggesting that broad-spectrum supplementation 
may have a greater anxiolytic effect in this measure of anxiety related behaviour than B 
vitamins alone. However there was no significant difference between the Berocca and control 
groups. The B vitamin group actually took longer to emerge than both vitamin C and control 
groups, but this was not statistically significant. It may be that high dose B vitamins alone 
could be eliciting an anxiogenic effect in this measure. 
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 In the OFT the Berocca group spent significantly less time in the corner squares than 
both B vitamin and control groups, but not vitamin C. The vitamin C group also spent less 
time in the corner squares than the B vitamin and control groups but this was not statistically 
significant. This suggests that, compared to the control condition, Berocca had an anxiolytic 
action in the OFT. Given that this action was greater than vitamin C alone, it suggests the 
combination of B and C in Berocca may act synergistically so that B enhances any anxiolytic 
effects of vitamin C reported in previous studies (Hughes et al., 2011). It may also be possible 
the combination of minerals (magnesium and zinc) in Berocca influenced the anxiolytic 
actions of vitamin C or even somehow exerted an anxiolytic effect on its own.  
 The only significant treatment effect in the EPM was that Berocca-treated rats spent 
significantly less time walking in the closed arms than control subjects. This suggests either 
the Berocca treatment had a small anxiolytic effect in the EPM, or that Berocca-treated rats 
spent more time in the middle of the maze (i.e. not in any arm), or more time immobile in the 
closed arms, compared to control. There were no significant differences in rearing in closed 
arms or rearing and walking in open arms between any of the treatment groups. Therefore, it is 
unlikely that there was any anxiolytic effect of Berocca treatment in the EPM, and it is more 
likely that animals were either spending more time immobile or in the middle of the maze. 
 For responsiveness to brightness change in a Y-maze, the Berocca group made a 
significantly higher percentage of entries into the changed arm than all other groups. The 
Berocca group also showed a significantly higher percentage of changed-arm occupancy than 
either the control or B vitamin group. The Berocca group occupied the changed arm for longer 
periods of time than the vitamin C group but this difference just failed to reach statistical 
significance (p= .051). The Berocca group also made a significantly higher number of entries 
into both arms (ambulation) than all other groups. Low ambulation is thought to be indicative 
of increased anxiety. These results suggest that Berocca may have both decreased anxiety and 
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improved memory in the Y maze. Berocca supplementation may have improved encoding, 
consolidation or retrieval of information or decreased neophobia arising from heightened 
emotional reactivity (or “anxiety”), as can occur with anxiogenic experiences in other 
situations (Aitken, 1974; Hughes, 1987; Missilin & Ropartz, 1981) thereby making the 
animals more comfortable in the novel environment (Atchinson & Hughes, 2006). Given the 
higher levels of ambulation in the Berocca group, and as activity is inversely related to anxiety 
(Archer, 1973), decreased anxiety in the Berocca treated animals may be the best way of 
accounting for all the behavior observed in the Y-maze.  
 These anxiolytic effects may be due to synergistic action of B vitamins with vitamin C, 
or the additional mineral content of Berocca on its own or its enhancement of the effects of 
vitamins B and C. The Y maze was the last behavioural test for the animals so it may also be 
that the significant results of Berocca in this test were due to a longer treatment time i.e. the 
animals had reached a threshold for treatment effects that had not been met in the OFT and 
EPM. 
 
6.1.3 Sex differences and interactions: 
 A number of sex differences and interactions were found in each of these tests. In the 
open field, females took significantly longer to emerge from the start box than males thus 
suggesting that they may be more anxious when exposed to open illuminated novel 
environment. However, once in the open field, they made significantly more transitions than 
males suggesting that (given lower ambulation is indicative of increased anxiety) they may 
have been less anxious than male rats. The number of faecal boluses left by females in the 
OFT was also significantly lower than males, which further supports the idea that females are 
less anxious than males once in the open field. 
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 In the EPM females spent significantly more time than males walking in open arms. 
Given there were no significant differences in rearing it is possible that males spent more time 
immobile in the open arms suggesting they were more anxious than females in the open arms. 
 In the Y maze there was a sex difference in ambulation and also sex x treatment 
interactions in percentages of entries into and occupancy of the changed arm. There was a 
significant difference in ambulation between males and females, with females making 
significantly more entries into both arms than males. There were significant interactions 
between sex and treatment in percentages of changed-arm entries and occupancy. These 
results indicate that males and females were affected differently by the different micronutrient 
treatments. Specifically, the percentage of changed-arm entries and occupancy for males was 
increased with Berocca treatment but decreased by B vitamin treatment. However for females 
the response was different. Both Berocca and B vitamin treatment increased the percentage of 
change arm occupancy compared to control, for females. This indicates B vitamin treatment 
was more effective for females than males in terms of anxiolytic and memory enhancing 
effects. However the addition of more nutrients in Berocca resulted in the anxiolytic and 
memory enhancing effects being of greater benefit to males. It may be that the additional 
minerals and vitamin C in the Berocca formulation provides greater anxiolytic benefit for 
males. 
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7.0 General Discussion: 
 
7.1 Methodological strengths: 
 The current study had several methodological strengths. The first was the use of rats. 
Rats develop quickly reaching adulthood in approximately 90 days (Anderson, 2003). 
Therefore research can be completed in a much shorter time period and the long-term 
behavioural effects of exposure can be examined faster than in human populations. Rats 
provide a number of advantages including overall control of experimental conditions, reducing 
confounding variables associated with humans such as non-compliance with treatment, missed 
appointments, prior history of medication use and illness, and no expectations about what the 
treatment might do. This ultimately limits a number of confounding variables that might be 
present in human populations. The use of rats allows us to ensure that all subjects are exposed 
to the same experiences (i.e. handling, living conditions) and that it is only the variables being 
manipulated that determine the results.  
 The use of a control group allowed investigation into whether the supplement was 
responsible for any behavioural effects in each treatment group. Having a control meant 
comparisons could be made between supplement groups and a group that had never taken the 
supplement. 
 The use of male and female rats allowed investigation into different effects of each 
supplement in each sex and this proved to be useful due to the sex differences and interactions 
that were found. This is important because the supplementation regimens here are intended for 
use by both sexes in a human population.  
 As mentioned in section 3.4 the validity and reliability of the behavioural measures 
adopted were high, thereby providing considerable confidence in the methodology.  
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 The rats were provided in one cohort thus avoiding any problems with them arriving at 
different times.  Consequently, all rats in each group began their treatment and were tested at 
the same time. This further limited the number of possible any confounding variables. 
 The use of different micronutrient formulas enabled the establishment of the most 
effective supplementation regimen in relation to the reduction of anxiety like behaviour and 
improvements in short term spatial memory in normal rat populations. Comparing B vitamins 
and vitamin C with Berocca (a combination of the two) which have all been shown to reduce 
anxiety in humans and rats (Carroll et al., 2000; Kennedy et al., 2010; Stough et al., 2011; 
Hughes et al., 2011) alongside the control animals allowed the assessment of whether a single 
nutrient or nutrient group is more effective than another in reducing anxiety or whether they 
act synergistically to have the greatest effects in reducing anxiety like behaviour in rats. 
Furthermore using doses of the B vitamins and Berocca that were higher than a therapeutic 
level (as determined by previous studies, Carroll et al., 2000; Kennedy et al., 2010) provided 
information regarding the effects of higher doses of micronutrient supplementation.  
 This study showed that receiving a high dose of a broad-spectrum micronutrient 
supplement gave the greatest reduction in anxiety-like behaviour and the most improvement in 
measures of short-term memory compared to single micronutrient supplementation.  Effects of 
single micronutrients did not differ greatly from controls and in some cases rats in these 
groups even performed worse than controls. It has been suggested that higher doses may have 
possible toxic effects and therefore produce greater anxiety (De Oliveria et al., 2007). This 
was possibly the case with the B vitamins, as treated rats exhibited poorer performance on 
some measures of anxiety than controls. However the broad-spectrum supplementation 
resulted in significantly improved performance. 
 The administration of supplements in the drinking water was another strength. This 
allowed exact measurement of the appropriate dose for each supplement to be easily dissolved 
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into the rats’ drinking water. It also made it very easy to calculate accurately how much each 
rat was drinking and subsequently the dose each rat was consuming. The manner in which rats 
were housed allowed social interaction but at the same time, because they each had their own 
drinking solution, individual doses could be calculated.  
 The presence of an observer during behavioural tests could conceivably have affected 
responding especially in the emergence latency and open field tests. To ensure this was kept to 
a minimum an external video camera was mounted above each apparatus and connected to a 
T.V. monitor in the experimental room where the observer was able to record movements 
without sitting in close proximity to either apparatus. The same testing room was also used for 
all tests and animals and the apparatus was oriented in the same location for every animal. 
 This study serves as a pilot for the behavioural effects of a broad spectrum versus 
single micronutrient supplement. No other research has been done in rats or humans in this 
specific area and consequentially little is known about the differences in behavioural effects 
between single and broad-spectrum micronutrients. The purpose of this study was to detect 
any differences between these micronutrient supplementation regimens and their long-term 
behavioural effects. As there is a lack of animal research in this area, the results should be 
viewed as preliminary and providing a starting point for future research. 
 
 
 
 
 
 
 
 
 89 
7.2 Methodological Limitations: 
 There were a number of limitations to the current study. Firstly, the rats were not 
weighed during treatment (only before and after) so the average dose consumed each week 
could not be calculated. An average dose for each week of treatment would have been useful 
for determining exactly how much of each micronutrient each group was consuming, and how 
this was related to the behavioural results. 
 One possible limitation might be the fact that the animals were drawn from a normal 
rat population. Because the majority of human research in this area has focused on individuals 
with psychiatric disorders, perhaps the use of an animal model of anxiety using genetic 
manipulation to produce animals with higher anxiety traits would provide more insight into 
the effects of different micronutrients on an anxious population. 
 Rats in each experimental group were not tested on each measure before treatment. 
Therefore there is no baseline of behavioural results for each treatment group. It is possible, 
but unlikely, that the two cohorts were significantly different in measures of anxiety and 
memory before treatment due to individual characteristic and genetic differences. Establishing 
a baseline measure of anxiety and memory would have allowed for control of these individual 
differences. However this could also be viewed as a strength as rats did not have a chance to 
become habituated and therefore less anxious in the experimental environment. 
 There were two factors that need to be considered with the micronutrient 
administration. First the Berocca may have tasted better, given it contains artificial sweeteners, 
which were not in the other treatment groups. This would explain the higher dose ingested by 
the Berocca group. Another limitation is that Berocca contains minerals (calcium, magnesium, 
and zinc). These comprised one variable that was not controlled which may have influenced 
the results. 
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7.3 Implications 
 This was a pilot study designed to assess the effects of broad spectrum and single 
micronutrient supplementation on behaviour in normal rats. There is a lack of research into the 
effects of vitamins on animal behaviour. The results of this study are therefore important and 
provide additional knowledge to a body of research with mixed results across a variety of 
individual vitamins and minerals and their effects on a number of measures of animal and 
human behaviour. The current study highlights some important issues and provides a base for 
future research. It is important that animal research into micronutrient supplementation is 
continued as it adds to our understanding of this area. This will be significant in the future as 
the number of studies looking at the effects of micronutrients in the human population 
increases. 
 This research provides a valuable stepping-stone in animal micronutrient research. It 
has helped to identify gaps in the literature that need addressing, and has highlighted some 
important considerations that need attention when planning future research. It highlights a 
need to establish a complete understanding of the effects of micronutrients. 
 The most significant findings of the current study were the effects of the Berocca 
treatment on measures of anxiety and memory in the responsiveness to brightness change in a 
Y maze test. Berocca treatment resulted in a significant reduction in anxiety and 
improvements in short term spatial memory compared with all other treatment groups and 
controls. In the Y maze there were also significant sex differences in ambulation, and a sex 
treatment interaction in the percentage of change arm entry and occupancy, suggesting 
different treatments affected each sex differently. Specifically, the percentage of changed-arm 
entries and occupancy for males was increased with Berocca treatment but decreased by B 
vitamin treatment. However for females the response was different. Both Berocca and B 
vitamin treatment increased the percentage of change arm occupancy compared to control, for 
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females. This indicates B vitamin treatment was more effective for females than males in 
terms of anxiolytic and memory enhancing effects. However the addition of more nutrients in 
Berocca resulted in the anxiolytic and memory enhancing effects being of greater benefit to 
males. It may be that addition minerals and vitamin C in the Berocca formulation provides 
greater anxiolytic benefit for males. 
 These results provide evidence that a broad-spectrum of micronutrients may be more 
effective than a single micronutrient or vitamin group in reducing anxiety-related behaviour 
and improving short-term memory in a normal rat population. The sex-treatment interactions 
also suggest that certain micronutrient treatments may be more appropriate for different sexes. 
Also noteworthy is that the Berocca group consumed on average a significantly higher dosage 
of both B vitamins and vitamin C than the two other treatment groups. This may explain some 
of the effects, as the B vitamin and vitamin C supplementation may have been below 
therapeutic levels. 
 Any potential biochemical mechanisms are unable to be identified from these results, 
given that the study was focused on behavioural effects rather than mechanisms of action. The 
study results do however suggest that the broad-spectrum rationale mentioned in section 1.6.1 
may be important to take into consideration with the effects of vitamins on anxiety-like 
behaviour and short-term spatial memory in rats. It is important to note that the broad-
spectrum group did consume higher doses of B vitamins and vitamin C that the single vitamin 
groups. This may implicate the usage of higher doses of these vitamins alone in future studies.  
 Overall the results from the current study suggest that a high dose of a broad spectrum 
micronutrient supplement is more effective in reducing anxiety and improving memory 
compared to single micronutrients or single micronutrient groups (B vitamins). However 
future research needs to be conducted to replicate these results before any firm conclusions are 
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made about the efficacy of a broad-spectrum micronutrient supplement over a single 
micronutrient supplement. 
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8.0 Future directions: 
  
 This was the first study comparing the effects of broad-spectrum versus a single 
micronutrient supplement on anxiety like behaviour and short-term memory in rats. Future 
research in this area is essential. Firstly future research should aim to address the limitations of 
the current study. From here the focus should be further animal studies to see if these results 
are able to be replicated, and to provide more evidence to support these findings. 
 Establishing a baseline for behaviour may be useful in the future to help determine 
more accurately whether behaviour was influenced by the intervention or through individual 
differences between different animal cohorts. This would involve running the behavioural tests 
prior to the intervention then comparing the results with behavioural tests following 
intervention. Future research may also benefit from the use of animals that have been bred to 
express anxious traits. There are a number of genetic models of anxiety in rodents (Cryan & 
Sweeny, 2011) that could be used. This would provide a better analogue for human anxiety 
and improve the face and construct validity of future studies. 
 Addressing the taste of the vitamin solution would also be useful. This could be done 
either by removing the artificial sweeteners from the Berocca and making it up in the 
laboratory, or adding sweeteners to the B vitamin and vitamin C mixtures. The former would 
be a better option to limit any confounding effects of artificial sweeteners. Making the broad-
spectrum supplement in the laboratory may also be useful, as it would allow the exclusion of 
the minerals in Berocca, thereby further reducing confounding variables. 
 Future research should endeavour to establish the effects of each individual vitamin 
and mineral in Berocca. This would mean testing each B vitamin alone as opposed to in a 
complex. While this would be difficult it could enable a clearer understanding of whether all 
the micronutrients in Berocca are needed together or not. This would give a more in-depth and 
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confident understanding of how micronutrients affect behaviour. It may add or detract to the 
rationale behind broad-spectrum supplementation, that nutrients are required together in 
balance.  
 Another area that would be useful to investigate is the length of treatment. Both longer 
and shorter treatment periods would provide a better idea as to a minimum effective period for 
optimal effect. 
 Once these issues have been adequately addressed in animals, research should then 
focus on the effects of broad-spectrum micronutrient supplementation compared to single 
micronutrient supplementation for anxiety in humans. The use of randomised placebo 
controlled trials, here may be helpful in determining if these effects are replicable in humans. 
This also gives a further option of examining a variety of different single micronutrients alone 
and comparing them to broad-spectrum supplementation. 
 There is a need for future research to investigate the biochemical mechanisms of 
micronutrient action. This could involve in-vitro investigations into specific effects of single 
micronutrients on brain tissues, including neurotransmitter pathways and potential antioxidant 
effects. In-vivo studies could test the same parameters with individual micronutrients and a 
broad-spectrum supplement to compare and elucidate any synergistic interactions between 
micronutrients. This may provide support for the mechanisms of action proposed by Kaplan 
and Leung (2011). 
 There have been recent investigations into potential mechanisms of micronutrient 
supplementation. Du et al (2015) have investigated the role of nutrients in protecting 
mitochondrial functioning and neurotransmitter signalling with implications in the treatment 
of depression, PTSD and suicidal behaviour. More research of this kind is needed to establish 
a more concrete idea of the mechanisms involved in the beneficial effects of micronutrient 
supplementation on mental illness. 
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 The growing fields of nutrigenetics and neutrogenomics may help offer insight into 
micronutrient mechanisms of action. These fields allow the development of a more targeted 
approach to micronutrient supplementation by mapping out genetic information. This would 
provide some insight into any genetic mutations that may cause in-born metabolic errors and 
micronutrient deficiencies, which can then be targeted with supplementations. The field of 
epigenetics offers promise, as does the use of omic genetic technologies. These areas include 
pharmacogenomics (how genes affect responses to drugs), proteomics (the study of proteins 
expressed by the genome) and metabolomics (chemical processes involving metabolites). 
Technologies in these areas could help to provide answers on pharmacodynamics properties, 
toxicity and safety effects, and the clinical efficacy of micronutrient supplementation. 
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9.0 Conclusions:  
 
 The most significant finding in the current study was that supplementation with a 
broad-spectrum (Berocca) micronutrient resulted in less emotionality and improved short-term 
spatial memory when compared to other treatment groups. Sex differences occurred, as did 
interactions between sex and micronutrient treatment group. The main outcome of the study is 
to favour the view that a broad-spectrum micronutrient supplement may be more effective in 
reducing anxiety and enhancing short-term spatial memory, than a single micronutrient, at 
least in a normal rat population. The sex x treatment interactions also suggested that certain 
micronutrients have different effects on anxiety and memory depending on the sex of the 
animal. These interactions suggested that B vitamin treatment was more effective for females 
than males in terms of anxiolytic and memory enhancing effects. However the addition of 
more nutrients in Berocca resulted in the anxiolytic and memory enhancing effects being of 
greater benefit to males. It may be that addition minerals and vitamin C in the Berocca 
formulation provided a greater anxiolytic benefit for males. 
 This was a pilot study and has highlighted a number of limitations that can be 
addressed in future research. The current study provides evidence that micronutrient 
supplementation does indeed affect behavioural responses in animals. Further research with 
randomized controlled designs in both animals and humans will help establish a greater 
understanding of these effects. Research into the mechanisms of action in the brain and body 
of micronutrients, alone and in combination will help to develop this understanding further. 
Together this knowledge may help provide insights into how micronutrient supplementation 
can be integrated into clinical practice. 
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